<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001016.pub2" GROUP_ID="MENSTR" ID="451799082509520976" MERGED_FROM="" MODIFIED="2008-11-07 09:06:39 +0100" MODIFIED_BY="Jane Clarke" NOTES="&lt;p&gt;Exported from Review Manager 4.2.2&lt;br&gt;Short title (no longer in use): Progestagens and menorrhagia&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2007-11-09 13:00:00 +0100" REVIEW_NO="152" REVMAN_SUB_VERSION="5.0.17 beta" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="5.0">
<COVER_SHEET MODIFIED="2008-11-07 09:06:39 +0100" MODIFIED_BY="Jane Clarke">
<TITLE>Cyclical progestogens for heavy menstrual bleeding</TITLE>
<CONTACT MODIFIED="2008-11-07 09:06:39 +0100" MODIFIED_BY="Jane Clarke"><PERSON ID="4773" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Anne</FIRST_NAME><LAST_NAME>Lethaby</LAST_NAME><POSITION>Systematic reviewer </POSITION><EMAIL_1>a.lethaby@auckland.ac.nz</EMAIL_1><ADDRESS><DEPARTMENT>Section of Epidemiology &amp; Biostatistics</DEPARTMENT><ORGANISATION>School of Population Health,University of Auckland</ORGANISATION><ADDRESS_1>Private Bag 92019</ADDRESS_1><CITY>Auckland</CITY><ZIP>1142</ZIP><COUNTRY CODE="NZ">New Zealand</COUNTRY><PHONE_1>+64 9 373 7599 ext 86333</PHONE_1><FAX_1>+64 9 373 7503</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2008-11-07 09:06:39 +0100" MODIFIED_BY="Jane Clarke"><PERSON ID="4773" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Anne</FIRST_NAME><LAST_NAME>Lethaby</LAST_NAME><POSITION>Systematic reviewer </POSITION><EMAIL_1>a.lethaby@auckland.ac.nz</EMAIL_1><ADDRESS><DEPARTMENT>Section of Epidemiology &amp; Biostatistics</DEPARTMENT><ORGANISATION>School of Population Health,University of Auckland</ORGANISATION><ADDRESS_1>Private Bag 92019</ADDRESS_1><CITY>Auckland</CITY><ZIP>1142</ZIP><COUNTRY CODE="NZ">New Zealand</COUNTRY><PHONE_1>+64 9 373 7599 ext 86333</PHONE_1><FAX_1>+64 9 373 7503</FAX_1></ADDRESS></PERSON><PERSON ID="14582" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Gill</FIRST_NAME><MIDDLE_INITIALS>A</MIDDLE_INITIALS><LAST_NAME>Irvine</LAST_NAME><POSITION>Consultant</POSITION><EMAIL_1>Gill.Irvine@aaaht.scot.nhs.uk</EMAIL_1><ADDRESS><DEPARTMENT>Obstetrics and Gynaecology</DEPARTMENT><ORGANISATION>Ayrshire Central Hospital</ORGANISATION><CITY>Irvine</CITY><ZIP>KA12 8SS</ZIP><REGION>Ayrshire</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 294 274191</PHONE_1><FAX_1>+44 294 313497</FAX_1></ADDRESS></PERSON><PERSON ID="14551" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Iain</FIRST_NAME><MIDDLE_INITIALS>T</MIDDLE_INITIALS><LAST_NAME>Cameron</LAST_NAME><POSITION>Professor</POSITION><EMAIL_1>itc@soton.ac.uk</EMAIL_1><EMAIL_2>hjh@soton.ac.uk</EMAIL_2><ADDRESS><DEPARTMENT>Department of Obstetrics and Gynaecology</DEPARTMENT><ORGANISATION>University of Southampton, Princess Anne Hospital</ORGANISATION><ADDRESS_1>Level F (815), Coxford Road</ADDRESS_1><CITY>Southampton</CITY><ZIP>SO16 5YA</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 23 8079 6044</PHONE_1><FAX_1>+44 23 8078 6933</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-11-07 09:05:36 +0100" MODIFIED_BY="Jane Clarke" NOTES="&lt;p&gt;New studies sought but none found: 12/12/03&lt;/p&gt;&lt;p&gt;Reformatted: 8/25/99&lt;/p&gt;">
<UP_TO_DATE>
<DATE DAY="25" MONTH="9" YEAR="2007"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="12" MONTH="12" YEAR="2003"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="" MONTH="" YEAR=""/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="1998"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="1998"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2008"/>
</DATES>
<WHATS_NEW NOTES="&lt;p&gt;Update: a new search was performed and no new trials identified in December 2003 and again in April 2007.&lt;br&gt;&lt;/p&gt;">
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="7" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="25" MONTH="9" YEAR="2007"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Department of Obstetrics and Gynaecology, University of Auckland, Auckland</NAME>
<COUNTRY CODE="NZ">New Zealand</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Health Research Council, Auckland</NAME>
<COUNTRY CODE="NZ">New Zealand</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT>
<SUMMARY>
<TITLE>Cyclical progestogens for heavy menstrual bleeding</TITLE>
<SUMMARY_BODY>
<P>Progestagens may offer some help in reducing heavy menstrual bleeding but are not as effective as other therapies such as danazol and tranexamic acid. Heavy menstrual bleeding (HMB) is when a woman looses 80 ml or more of blood per menstrual cycle (period). Most women with HMB do not show any physical cause so getting help without surgery is an attractive alternative. Progestogens are taken by mouth either during days 15 or 16 to day 26 of the menstrual cycle (short course) or from day 5 to day 26 (long course). The review of trials found that progestogens significantly reduced menstrual blood loss but were less effective than danazol, tranexamic acid and the progesterone-releasing intrauterine system (IUS). </P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>Excessively heavy menstrual bleeding (HMB) or menorrhagia is an important cause of ill health in women. Eighty per cent of women treated for HMB have no anatomical pathology, which makes medical therapy, with the avoidance of possibly unnecessary surgery, an attractive alternative. Of the wide variety of medications used to reduce heavy menstrual bleeding, oral progestogens are the most commonly prescribed. This review assesses the effectiveness of two different regimens of oral progestogens in reducing ovulatory HMB. </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>The primary objective of this review was to investigate the effectiveness of oral progestogen therapy taken either during the luteal phase or for a longer course of 21 days in achieving a reduction in menstrual blood loss in women of reproductive years with heavy menstrual bleeding (HMB).</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>We searched the Cochrane Menstrual Disorders and Subfertility Group Trials Register (searched April 2007), MEDLINE (1966 to April 2007) and EMBASE (1985 to April 2007). Attempts were also made to identify trials from citation lists of review articles. In most cases, the first author of each included trial was contacted. </P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>The inclusion criteria were randomised comparisons of oral progestogen therapy versus placebo or other medical treatments in women of reproductive years with regular heavy periods measured either objectively or subjectively and with no pathological or iatrogenic causes for their heavy menstrual blood loss.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Seven randomised controlled trials (RCTs) were identified that fulfilled the inclusion criteria. The review authors extracted the data independently. Odds ratios for dichotomous outcomes and weighted mean differences for continuous outcomes were estimated from the data. </P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>No RCTs comparing progestogen treatment with placebo were identified. Comparisons between oral progestogens and other medical therapies were assessed separately according to dosage regimen. </P>
<P>Progestogen therapy during the luteal phase was significantly less effective at reducing menstrual blood loss when compared with tranexamic acid, danazol and the progesterone-releasing intrauterine system (IUS). Duration of menstruation was significantly longer with the progesterone IUS when compared with oral progestogen therapy but significantly shorter with danazol treatment. Adverse events were significantly more likely with danazol when compared with progestogen treatment. Progestogen therapy from day 5 to day 26 of the menstrual cycle was significantly less effective at reducing menstrual blood loss than the IUS. A significantly higher proportion of norethisterone (NET) patients taking progestogens found their treatment unacceptable compared to IUS patients. However, the adverse effects of breast tenderness and intermenstrual bleeding were more likely in women with the IUS. </P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Progestogens administered from day 15 or 19 to day 26 of the cycle offer no advantage over other medical therapies such as danazol, tranexamic acid, non-steroidal anti-inflammatory drugs (NSAIDs) and the IUS in the treatment of menorrhagia in women with ovulatory cycles. Progestogen therapy for 21 days of the cycle results in a significant reduction in menstrual blood loss, although women found the treatment less acceptable than intrauterine levonorgestrel. This regimen of progestogen may have a role in the short-term treatment of menorrhagia. </P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY>
<BACKGROUND>
<P>Excessively heavy menstrual bleeding (menorrhagia) is an important cause of ill health in women. One in 20 women aged 30 to 49 years consults their general practitioner (GP) each year with menorrhagia (<LINK REF="REF-Vessey-1992" TYPE="REFERENCE">Vessey 1992</LINK>) and it accounts for 12% of all gynaecology referrals (<LINK REF="REF-Bradlow-1992" TYPE="REFERENCE">Bradlow 1992</LINK>). </P>
<P>Menorrhagia or heavy menstrual bleeding (HMB) is objectively defined as greater than or equal to 80 ml blood loss per menstrual cycle (<LINK REF="REF-Cole-1971" TYPE="REFERENCE">Cole 1971</LINK>; <LINK REF="REF-Hallberg-1966" TYPE="REFERENCE">Hallberg 1966</LINK>); but it is the woman's perception of her own menstrual loss which is the key determinant in her referral and indeed subsequent treatment. Many factors can cause abnormal menstruation (including coagulation disorders, endocrine disorders, uterine abnormalities and other pelvic diseases) and these disorders are usually considered before decisions are made about treatment. Eighty per cent of women treated for HMB have no anatomical pathology and over a third of the women undergoing hysterectomies for menorrhagia have normal uteri removed (<LINK REF="REF-Clarke-1995" TYPE="REFERENCE">Clarke 1995</LINK>; <LINK REF="REF-Gath-1982" TYPE="REFERENCE">Gath 1982</LINK>). Hence, medical therapy, with the avoidance of possibly unnecessary surgery, is an attractive alternative. </P>
<P>A wide variety of medications are used to reduce heavy menstrual bleeding. In the UK, norethisterone (norethindrone in the USA) is the most commonly prescribed drug and progestogens make up 55% in total of prescriptions for menorrhagia (<LINK REF="REF-Coulter-1995" TYPE="REFERENCE">Coulter 1995</LINK>). However, the role and efficacy of oral progestogens in treating all cases of unexplained heavy bleeding remains controversial and there is little objective evidence to support the use of this therapy. </P>
<P>In the anovulatory woman, progestogens help to coordinate regular uterine shedding when given as a late luteal replacement treatment, on days 19 to 26 of the cycle (<LINK REF="REF-Conyngham-1965" TYPE="REFERENCE">Conyngham 1965</LINK>). However, the use of progestogens as luteal phase supplementation in the ovulatory woman with menorrhagia is more questionable. Consequently, an increase in the duration and dosage of progestogen therapy has recently been investigated in patients with ovulatory HMB. </P>
<P>Prolonged use of high-dose progestogens is sometimes associated with side effects, which include fatigue, mood changes, weight gain, nausea, bloating, oedema, headaches, depression, loss of libido, irregular bleeding and atherogenic changes in the lipid profile. </P>
<P>The aim of this review was to determine the efficacy of progestogen therapy in the reduction of menstrual blood loss in women with symptomatic HMB. </P>
</BACKGROUND>
<OBJECTIVES>
<P>To determine the effectiveness of oral progestogen therapy in achieving a reduction in menstrual blood loss in women of reproductive age with heavy menstrual bleeding. </P>
<P>We wished to test the following hypotheses. <BR/>(1) Treatment with oral progestogens is more effective than placebo in reducing menstrual blood loss. <BR/>(2) Treatment with oral progestogens is more effective than other medical therapies (antifibrinolytics, danazol, combined oral contraceptives, progesterone and the progestogen-releasing intrauterine system (IUS), non-steroidal anti-inflammatory drugs (NSAIDs), gonadotropin releasing hormone (GNRH) analogues) in reducing menstrual blood loss. <BR/>(3) Treatment with oral progestogens is associated with a lower incidence of adverse events and higher compliance and acceptability than with other medical therapies. <BR/>(4) Treatment with oral progestogens is more cost effective than other medical therapies in treating menorrhagia. <BR/>(5) Treatment with oral progestogens leads to an improved quality of life for women with menorrhagia. </P>
<P>We also wished to estimate the size of any treatment effects. </P>
</OBJECTIVES>
<METHODS>
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>(1) All randomised controlled comparisons of oral progestogen therapies when used to reduce heavy menstrual bleeding versus placebo. <BR/>(2) All randomised controlled comparisons of oral progestogen therapies versus other medical therapies when used to reduce heavy menstrual bleeding. </P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<UL>
<LI>Recruited from women of reproductive years</LI>
<LI>Recruited from women with regular heavy periods measured either subjectively by the patient or objectively by the alkaline haematin method (more than 80 ml per cycle) (<LINK REF="REF-Hallberg-1964" TYPE="REFERENCE">Hallberg 1964</LINK>; <LINK REF="REF-Newton-1977" TYPE="REFERENCE">Newton 1977</LINK>)</LI>
<LI>Recruited from women attending primary care, family planning or specialist clinics</LI>
</UL>
<P>
<BR/>Exclusion criteria</P>
<UL>
<LI>Post-menopausal bleeding (less than one year from the last period) </LI>
<LI>Irregular menses and intermenstrual bleeding</LI>
<LI>Pathological causes of menorrhagia</LI>
<LI>Iatrogenic causes of menorrhagia</LI>
</UL>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>(1) Oral progestogen therapy (norethisterone, dydrogesterone, medroxyprogesterone) versus placebo </P>
<P>(2) Oral progestogen therapy versus any other medical therapy (antifibrinolytic agents, danazol, NSAIDs, gonadotrophin releasing hormone analogues, combined oral contraceptives, progesterone and progestogen-releasing intrauterine systems) </P>
<P>Variable doses and lengths of administration of treatments were considered. Oral progestogens can be given as luteal phase replacement treatment (days 19 to 26 or days 15 to 25 of the menstrual cycle), as a longer course of 22 out of 28 days (days 5 to 26 of the cycle) or continuously until a heavy bleeding episode is controlled then followed by a maintenance dose. </P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>Each of the following outcomes were recorded, where available. </P>
<P>
<I>Primary outcomes </I>
<BR/>(1) Menstrual blood loss <BR/>
</P>
<UL>
<LI>Objective assessment of blood loss, measured either during the intervention or for up to one year of follow up after the intervention by the alkaline haematin method or the pictorial chart method (<LINK REF="REF-Higham-1990" TYPE="REFERENCE">Higham 1990</LINK>) </LI>
<LI>Subjective (patient perception) assessment of blood loss, also measured either during the intervention or for up to one year of follow up after the intervention </LI>
</UL>
<P>
<BR/>
<I>Secondary outcomes </I>
<BR/>(1) Number of days bleeding during the intervention menstrual cycle <BR/>(2) Quality of life: patients' perceived change in quality of life provided this was recorded in a reproducible and validated format <BR/>(3) Patient compliance with treatment <BR/>(4) Patient acceptability of treatment <BR/>(5) Adverse events, of any degree, reported either spontaneously by the patient or elicited from specific questioning <BR/>(6) Mortality <BR/>(7) Resource use and cost </P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS>
<P>For the update of this review in 2007, we searched the Cochrane Menstrual Disorders and Subfertility Group Trials Register (searched April 2007) which is submitted as part of the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library), MEDLINE (1966 to April 2007) and EMBASE (1985 to April 2007). No new trials were identified. </P>
<P>The following terms were included in the electronic search strategy: </P>
<P>MEDLINE(R)</P>
<P>1 menorrhagia/ <BR/>2 menorrhag$.tw. <BR/>3 (menstrua$ adj5 (bleed$ or blood)).tw. <BR/>4 (heavy adj5 menstrua$).tw. <BR/>5 (dysfunctional adj5 uter$).tw. <BR/>6 hypermenorrh$.tw. <BR/>7 or/1-6 <BR/>8 exp Progestins/ <BR/>9 (Progestin$ or progestogen$ or progesterone or norethisterone or norethindrone or dydrogesterone or medroxyprogesterone).tw.<BR/>10 (progestagen$ or progestational).tw)<BR/>11 or/8-10 <BR/>12 7 and 11 <BR/>13 randomized controlled trial.pt. <BR/>14 controlled clinical trial.pt. <BR/>15 Randomized Controlled Trials/ <BR/>16 Random allocation/<BR/>17 Double-blind method/ <BR/>18 Single-blind method/ <BR/>19 or/13-18<BR/>20 clinical trial.pt. <BR/>21 exp clinical trials/ <BR/>22 (clin$ adj25 trial$).ti,ab,sh. <BR/>23 ((singl$ or doubl$ or tripl$ or trebl$) adj25 (blind$ or mask$)).ti,ab,sh. <BR/>24 Placebos/ <BR/>25 placebo$.ti,ab,sh. <BR/>26 random$.ti,ab,sh.<BR/>27 Research design/ <BR/>28 or/20-27 <BR/>29 animal/ not (human/ and animal/) <BR/>30 19 or 28 <BR/>31 30 not 29<BR/>32 12 and 31<BR/>33 (2003$ or 2004$ or 2005$ or 2006$ or 2007$).ed. <BR/>34 32 and 33 (<BR/>35 from 34 keep 1-39 </P>
<P>Cochrane Central Register of Controlled Trials (CENTRAL)</P>
<P>1 menorrhagia/ <BR/>2 menorrhag$.tw. <BR/>3 (menstrua$ adj5 (bleed$ or blood)).tw. <BR/>4 (heavy adj5 menstrua$).tw. <BR/>5 (dysfunctional adj5 uter$).tw.<BR/>6 hypermenorrh$.tw. (<BR/>7 or/1-6 <BR/>8 exp Progestins/ <BR/>9 (Progestin$ or progestogen$ or progesterone or norethisterone or norethindrone or dydrogesterone or medroxyprogesterone).tw. <BR/>10 (progestagen$ or progestational).tw.<BR/>11 or/8-10 <BR/>12 7 and 11 <BR/>13 from 12 keep 1-109 </P>
<P>CINAHL - Cumulative Index to Nursing &amp; Allied Health Literature </P>
<P>1 menorrhagia/ <BR/>2 menorrhag$.tw. <BR/>3 (menstrua$ adj5 (bleed$ or blood)).tw.<BR/>4 (heavy adj5 menstrua$).tw. <BR/>5 (dysfunctional adj5 uter$).tw. <BR/>6 hypermenorrh$.tw. <BR/>7 or/1-6 <BR/>8 exp Progestins/ <BR/>9 (Progestin$ or progestogen$ or progesterone or norethisterone or norethindrone or dydrogesterone or medroxyprogesterone).tw. <BR/>10 (progestagen$ or progestational).tw.<BR/>11 or/8-10 <BR/>12 7 and 11 <BR/>13 exp clinical trials/<BR/>14 Clinical trial.pt.<BR/>15 (clinic$ adj trial$1).tw. <BR/>16 ((singl$ or doubl$ or trebl$ or tripl$) adj (blind$3 or mask$3)).tw. <BR/>17 Randomi?ed control$ trial$.tw. <BR/>18 Random assignment/ <BR/>19 Random$ allocat$.tw. <BR/>20 Placebo$.tw. <BR/>21 Placebos/ <BR/>22 Quantitative studies/<BR/>23 Allocat$ random$.tw.<BR/>24 or/13-23 <BR/>25 12 and 24<BR/>26 from 25 keep 1-19 </P>
<P>EMBASE </P>
<P>1 menorrhagia/ <BR/>2 menorrhag$.tw. <BR/>3 (menstrua$ adj5 (bleed$ or blood)).tw. <BR/>4 (heavy adj5 menstrua$).tw. <BR/>5 (dysfunctional adj5 uter$).tw. <BR/>6 hypermenorrh$.tw. <BR/>7 or/1-6 <BR/>8 (Progestin$ or progestogen$ or progesterone or norethisterone or norethindrone or dydrogesterone or medroxyprogesterone).tw. <BR/>9 (progestagen$ or progestational).tw. <BR/>10 exp Gestagen/ <BR/>11 or/8-10 <BR/>12 7 and 11 <BR/>13 Controlled study/ or randomized controlled trial/ <BR/>14 double blind procedure/ <BR/>15 single blind procedure/ <BR/>16 crossover procedure/ <BR/>17 drug comparison/ <BR/>18 placebo/ <BR/>19 random$.ti,ab,hw,tn,mf. <BR/>20 latin square.ti,ab,hw,tn,mf. <BR/>21 crossover.ti,ab,hw,tn,mf. <BR/>22 cross-over.ti,ab,hw,tn,mf. <BR/>23 placebo$.ti,ab,hw,tn,mf. <BR/>24 ((doubl$ or singl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).ti,ab,hw,tn,mf. <BR/>25 (comparative adj5 trial$).ti,ab,hw,tn,mf. <BR/>26 (clinical adj5 trial$).ti,ab,hw,tn,mf. <BR/>27 or/13-26 <BR/>28 nonhuman/ <BR/>29 animal/ not (human/ and animal/) <BR/>30 or/28-29 <BR/>31 27 not 30 <BR/>32 12 and 31<BR/>33 (2003$ or 2004$ or 2005$ or 2006$ or 2007$).em. <BR/>34 32 and 33 <BR/>35 from 34 keep 1-236 </P>
<P>Citation lists of included trials and relevant review articles were also searched. For most of the included trials, the first author was contacted to clarify issues relating to data extraction.</P>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>
<B>Selection of studies<BR/>
</B>
<BR/>Two of the review authors (GI and IC) are content experts. One review author has statistical expertise (AL). The selection of trials for inclusion in the review was performed by two review authors (AL and GI) after employing the search strategy described previously. </P>
<P>
<B>Methodological quality and data extraction</B>
<BR/>Included trials were analysed for the following criteria and methodological details.</P>
<P>
<B>
<I>Trial characteristics </I>
</B>
<BR/>(1) Method of randomisation<BR/>(2) Presence or absence of blinding to treatment allocation<BR/>(3) Quality of allocation concealment<BR/>(4) Number of patients randomised, excluded or lost to follow up<BR/>(5) Whether an intention-to-treat analysis was done<BR/>(6) Whether a power calculation was done<BR/>(7) Duration, timing and location of the study</P>
<P>
<B>
<I>Characteristics of the study women</I>
</B>
<BR/>(1) Age and any other recorded characteristics of women in the study<BR/>(2) Methods used to define heavy menstrual loss<BR/>(3) Other inclusion criteria<BR/>(4) Exclusion criteria</P>
<P>
<B>
<I>Interventions used</I>
</B>
<BR/>(1) Types of medical therapy used<BR/>(2) Dose, duration and timing of administration of medical therapy</P>
<P>
<B>
<I>Outcomes</I>
</B>
<BR/>(1) Methods used to measure menstrual blood loss at or after intervention<BR/>(2) Methods used to evaluate patient satisfaction, symptoms and change in quality of life</P>
<P>All assessments of the quality of trials and data extraction were performed independently by two review authors (AL and GI) using forms designed according to Cochrane guidelines. The quality of allocation concealment was graded as either A (adequate), B (unclear) or C (inadequate). Where necessary, additional information on trial methodology or actual trial data were sought from the principal author of any trial which appeared to meet the eligibility criteria. </P>
<P>
<B>Analysis</B>
</P>
<P>Statistical analysis was performed in accordance with the guidelines for statistical analysis developed by the Menstrual Disorders and Subfertility Group. Heterogeneity between the results of different studies was examined by inspecting the scatter in the data points and the overlap in their confidence intervals and, more formally, by checking the results of the chi-squared tests. A priori, it was planned to look at the possible contribution of differences in trial design to any heterogeneity identified in this manner. Where possible, the outcomes were pooled statistically. </P>
<P>For dichotomous data (for example proportion of patients who found the treatment unacceptable), results for each study were expressed as an odds ratio (OR) with 95% confidence intervals (CI) and combined for meta-analysis with RevMan software using the Peto-modified Mantel-Haenszel method. The negative consequences of these outcomes were recorded but for some outcomes, for example the proportion of women who had no subjective improvement in menstrual blood loss and the proportion who had no improvement in quality of life, the positive consequences for women (for example women who had improved quality of life) made more logical sense. However, consistency in the presentation of graphs summarising the meta-analysis was an important issue, where results to the left of the line could be interpreted as favouring the experimental group that received oral progestogen therapy and results to the right of the line favoured the control or other comparison group. </P>
<P>Difficulties were encountered with the reporting of continuous outcomes (for example menstrual blood loss after treatment). Meta-analysis with RevMan software uses a weighted mean difference (WMD) to combine outcomes and requires data to be presented as absolute values of post-treatment means with their standard deviations (SD). For some outcomes, particularly menstrual blood loss, the data is skewed and authors correctly presented their data as medians with a range. Where possible, original data were obtained from the principal authors but post-treatment means and standard deviations were not always either available or calculable. Where only medians and ranges were available, the median was regarded as being identical to the mean and a crude estimate of the standard deviation was calculated from the range ((range X 0.95)/4). This method is not ideal for skewed data and is likely to result in an over-estimation of the SD but it was planned a priori to perform sensitivity analysis with and without these trials included in the meta-analysis. Without exception, the distribution of data on menstrual blood loss is usually skewed and the ideal and most appropriate statistical analysis is probably nonparametric rather than inclusion in a meta-analysis assessing a weighted mean difference. </P>
<P>As the number of trials assessing the effects of oral progestogens was small, limited sensitivity analyses were planned. However, sensitivity analyses of trials with adequate methodology versus those of poor methodology (unequal groups at baseline and high proportion of exclusions) and of trials with reported means and standard deviations versus those with estimated means and SDs were conducted. </P>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION>
<P>Seven randomised controlled trials of oral progestogen therapy for regular heavy menstrual bleeding were identified and met the criteria for inclusion in the review. Summary details of the trials are given in the 'Characteristics of included studies' table. No trials were excluded. </P>
<P>There were no RCTs comparing oral progestogens with placebo. </P>
<P>
<B>Luteal progestogens <BR/>
</B>Six RCTs with a total of 252 women assessed the effects of oral progestogen therapy administered during the luteal phase of the menstrual cycle (between days 15 or 19 and day 26 of the menstrual cycle). Three of these compared norethisterone (NET) with danazol; one with mefenamic acid; one with tranexamic acid; and one trial with small numbers compared NET with danazol, mefenamic acid and a progesterone-releasing intrauterine system (Progestasert). One of the danazol trials compared NET with two separate danazol groups: a continuous regimen of 200 mg/day for three cycles and a reducing regimen of 200 mg/day for the first cycle, 100 mg/day during the next cycle and 50 mg/day during the last cycle. Norethisterone was the only type of oral progestogen that was assessed. </P>
<P>All women were pre-menopausal with a complaint of heavy menstrual bleeding. In three of the six trials, menorrhagia was confirmed as MBL more than 80 ml per cycle over two cycles by the alkaline haematin method, to satisfy the criteria for inclusion (one of these was after randomisation); one trial set a lower level of MBL more than 50 ml per cycle measured over two cycles and two required a subjective assessment (more than three or five pads or tampons per day, presence of flooding or clots on any day of the cycle, presence of secondary anaemia and blood loss that was socially and domestically disruptive). Most of the studies required that women have regular menstrual cycles and be free of underlying pathological conditions. </P>
<P>The dosage and duration of the NET regimen did not vary very much between studies. In two studies, women took 5 mg of NET three times daily between days 19 and 26 of the cycle, in two studies 5 mg of NET was taken twice daily during days 19 to 26 of the cycle and in two studies a slightly longer course of 5 mg twice daily was taken between days 15 or 16 and 25 of the cycle. Length of treatment was either two or three cycles. </P>
<P>In all but two of the trials, MBL during treatment was measured objectively by the alkaline haematin method. One trial did not assess blood loss and the other trial reported a bleeding intensity score, which was not recorded in this review. Five trials assessed both duration of menstruation in days and adverse events, three assessed compliance with treatment, two trials assessed subjective improvement in MBL and one trial assessed change in quality of life. </P>
<P>Quality of life measures were based on the results of patient questionnaires. In this study, patients were asked to assess whether their responses on general health, amount of flooding and leaking experienced, abdominal pain, limitation of their social activities and effect of heavy bleeding on their sex life were more favourable after treatment (Preston 1995). </P>
<P>
<B>Progestogens from day 5 to day 26 </B>
<BR/>One trial (Irvine 1998) compared the effects of norethisterone 5 mg taken three times daily over 21 days, from day 5 to day 26 of the menstrual cycle, with the levonorgestrel intrauterine system (Mirena) in 44 patients. This trial assessed menstrual blood loss with treatment, incidence of adverse events, change in quality of life (proportion of patients who stated that their periods interfered with their daily life) and treatment acceptability. </P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>Four trials received an allocation score of A based on adequate concealment prior to randomisation (<LINK REF="STD-Cameron-1990" TYPE="STUDY">Cameron 1990</LINK>; <LINK REF="STD-Higham-1993" TYPE="STUDY">Higham 1993</LINK>; <LINK REF="STD-Irvine-1998" TYPE="STUDY">Irvine 1998</LINK>; <LINK REF="STD-Preston-1995" TYPE="STUDY">Preston 1995</LINK>). Three of these trials also reported an intention-to-treat analysis and two trials had a power calculation for sample size. However, one of these trials (<LINK REF="STD-Preston-1995" TYPE="STUDY">Preston 1995</LINK>) had a very high dropout rate (more than 50%) after randomisation. In this trial, 103 patients were randomised to two parallel groups, either NET or tranexamic acid, and proceeded to take placebo medication for two menstrual cycles. Fifty-seven of the participants (55%) were then excluded from the treatment phase because the measured MBL was less than 80 ml/cycle, there was poor compliance or lack of ovulation. </P>
<P>The remaining three trials received an allocation score of B since the method of randomisation was not reported in the publication and in two cases the authors could not be contacted. The other trial (<LINK REF="STD-Cameron-1987" TYPE="STUDY">Cameron 1987</LINK>) reported marked differences in MBL at baseline between treatment groups. </P>
<P>One trial had single blinding (<LINK REF="STD-Higham-1993" TYPE="STUDY">Higham 1993</LINK>), one had double blinding (<LINK REF="STD-Preston-1995" TYPE="STUDY">Preston 1995</LINK>) and the remainder were not blinded. All included trials used a parallel group design. </P>
<P>Three trials did not report whether there were any exclusions following randomisation or loss to follow up. In two other trials, 5% (plus additional 18% lost to follow up but included in an intention-to-treat analysis) and 55% (see above) were excluded after randomisation. Another trial also reported a large proportion of exclusions from analysis; 20% were excluded after randomisation (two because the selection criteria were not met and four for personal reasons) and a further 27% were lost to follow up (all because of adverse events). The trial with the higher dosage of NET (<LINK REF="STD-Irvine-1998" TYPE="STUDY">Irvine 1998</LINK>) reported 18% withdrawal before the end of treatment and an additional 5% that completed their treatment but did not provide data on their final menstrual loss, although they were included in an intention-to-treat analysis for most of the outcomes. </P>
<P>Original data were provided by the authors of two trials. In one case, means and SDs were computed from the data provided by the author since only medians and ranges were reported in the publication (<LINK REF="STD-Cameron-1990" TYPE="STUDY">Cameron 1990</LINK>). Extra data from the other trial (<LINK REF="STD-Higham-1993" TYPE="STUDY">Higham 1993</LINK>) allowed the assessment of additional outcomes not reported in the publication. </P>
<P>Sensitivity analysis including and excluding the studies of lower quality (where comparison groups had marked differences in MBL at baseline (<LINK REF="STD-Cameron-1987" TYPE="STUDY">Cameron 1987</LINK>) and where a large proportion of patients were excluded or lost to follow up (<LINK REF="STD-Bonduelle-1991" TYPE="STUDY">Bonduelle 1991</LINK>)) did not change the direction of the results. However, some adverse event comparisons were solely reported by the latter study in the meta-analysis. The other lower quality study (<LINK REF="STD-Preston-1995" TYPE="STUDY">Preston 1995</LINK>), where a large proportion of participants were excluded after randomisation, compared progestogen therapy with tranexamic acid and was the only trial with this comparison entered in the meta-analysis. In addition, sensitivity analysis was performed including and excluding the sole study (<LINK REF="STD-Cameron-1987" TYPE="STUDY">Cameron 1987</LINK>) where means and SDs were estimated from the reported median and range; the results of the meta-analysis did not change markedly. </P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>
<B>
<BR/>Oral progestogen therapy versus placebo </B>
<BR/>There were no comparisons of oral progestogen therapy with placebo. </P>
<P>
<B>Oral progestogen therapy versus other medical therapies</B> <BR/>
<B>
<I>Menstrual blood loss (both objectively measured and subjectively assessed) </I>
</B>
<BR/>The goal of medical therapy is to reduce menstrual blood loss in women with heavy menstrual bleeding. Mean menstrual blood loss (as measured by the alkaline haematin method) was significantly greater with luteal progestogen therapy when compared to treatment with danazol, tranexamic acid and the progesterone-releasing IUS (WMD 55.6 ml, 95% CI 14.7 to 96.5; WMD 111 ml, 95% CI 43.5 to 178.5; WMD 51 ml, 95% CI 18.4 to 83.6, respectively). There was also a strong trend towards greater efficacy with NSAID therapy but this did not achieve statistical significance. Luteal progestogens were associated with a significantly greater blood loss than with danazol, using patients' own subjective assessments (OR 4.2, 95% CI 1.5 to 12.0). </P>
<P>In the trial with a longer regimen of progestogen, menstrual blood loss was significantly greater under this treatment compared with the levonorgestrel-releasing intrauterine system (LNG IUS), although there was a huge reduction from baseline for both groups. These results are not included in the graphical display but are located in the 'Other data' section of the review, in text form, because the data were not normally distributed. A higher proportion of the women in the LNG IUS groups had their periods reduced to 'normal' (that is &lt; 80 ml/cycle) than the groups treated with oral progestogens. </P>
<P>
<B>
<I>Duration of menstruation </I>
</B>
<BR/>Duration of menstruation was not significantly different during luteal progestogen therapy when compared with NSAIDs but in one small study menstruation was longer with the progesterone-releasing IUS (WMD -5 days, 95% CI -6.2 to -3.8). Duration of menstruation was significantly shorter under danazol therapy when compared with luteal progestogen therapy (WMD 1.6 days, 95% CI 1.1 to 2.1). </P>
<P>
<B>
<I>Compliance or acceptability </I>
</B>
<BR/>Compliance was assessed in a luteal progestogen versus NSAID comparison and in a luteal progestogen versus danazol comparison but no significant differences were found. By contrast, a lower proportion of the longer regimen NET group found the treatment acceptable when compared with the LNG IUS group (OR 8.6, 95% CI 2.5 to 29.5). </P>
<P>
<B>
<I>Adverse events and quality of life </I>
</B>
<BR/>The total number of adverse events was assessed for danazol, NSAIDs and tranexamic acid when compared with luteal progestogen therapy. There were significantly more adverse events under danazol in comparison with progestogen therapy (OR 0.34, 95% CI 0.13 to 0.88) but no other differences were found for the other comparisons. Many of the listed adverse events were also significantly less likely with progestogen therapy than with danazol: headaches, gastrointestinal effects, weight gain and skin changes; but breast changes were more likely under progestogen therapy. There were no other significant differences in individual adverse events for the other comparisons. </P>
<P>There was a lower incidence of the two adverse effects of intermenstrual bleeding and breast tenderness in the longer-course NET treated group than in the LNG IUS group (OR 0.23, 95% CI 0.05 to 0.99; OR 0.11, 95% CI 0.03 to 0.5, respectively). </P>
<P>Two trials, of luteal progestogens versus tranexamic acid and longer-course NET versus LNG IUS, assessed change in quality of life from patients' assessments. In the first trial, there were no significant differences for improvement in general health, dysmenorrhoea symptoms or ability to enjoy social activities, but a consistent trend was shown in favour of tranexamic acid; improvement in sex life and in flooding and leakage problems was greater during tranexamic acid treatment. In the second trial, there were no differences after treatment in the proportions who reported that their periods interfered with their daily life. </P>
<P>Use of resources and cost were not assessed by any studies. <B>
<BR/>
</B>
</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>This review illustrates the importance of conducting objective randomised controlled trials (RCTs) of medical therapy for the treatment of menorrhagia. The first subjective study using progestogens for the treatment of menorrhagia was published in 1960 (<LINK REF="REF-Bishop-1960" TYPE="REFERENCE">Bishop 1960</LINK>). It was not until 27 years later that a randomised study using objective measurements of menstrual blood loss was carried out (<LINK REF="STD-Cameron-1987" TYPE="STUDY">Cameron 1987</LINK>), demonstrating no significant reduction in menstrual blood loss with norethisterone 5 mg twice daily from days 15 to 25 of the cycle. Despite this, and the other papers included in this review, norethisterone remains the most commonly prescribed therapy for the treatment of menorrhagia by United Kingdom general practitioners (<LINK REF="REF-Coulter-1995" TYPE="REFERENCE">Coulter 1995</LINK>) and New Zealand gynaecologists (<LINK REF="REF-Farquhar-1996" TYPE="REFERENCE">Farquhar 1996</LINK>). </P>
<P>
<B>Trial design</B>
<BR/>In general, the trials were of variable quality. In two trials the method of randomisation was not stated (<LINK REF="STD-Bonduelle-1991" TYPE="STUDY">Bonduelle 1991</LINK>; <LINK REF="STD-Buyru-1995" TYPE="STUDY">Buyru 1995</LINK>) and in two other studies the author gave additional details regarding randomisation on request (<LINK REF="STD-Cameron-1987" TYPE="STUDY">Cameron 1987</LINK>; <LINK REF="STD-Cameron-1990" TYPE="STUDY">Cameron 1990</LINK>). In one of these trials the method of randomisation resulted in a marked difference in baseline menstrual blood loss (<LINK REF="STD-Cameron-1987" TYPE="STUDY">Cameron 1987</LINK>). The assigned treatment was adequately concealed prior to allocation in only four trials (<LINK REF="STD-Cameron-1990" TYPE="STUDY">Cameron 1990</LINK>; <LINK REF="STD-Higham-1993" TYPE="STUDY">Higham 1993</LINK>; <LINK REF="STD-Irvine-1998" TYPE="STUDY">Irvine 1998</LINK>; <LINK REF="STD-Preston-1995" TYPE="STUDY">Preston 1995</LINK>). Because of the different treatment regimens, it was difficult to blind patients to treatment since some therapies were taken during menses, others were taken for differing durations of treatment throughout the rest of the menstrual cycle and two studies required the fitting of a medicated intrauterine system. Single blinding to treatment allocation was achieved in one study (<LINK REF="STD-Higham-1993" TYPE="STUDY">Higham 1993</LINK>) and a further trial was double blinded (<LINK REF="STD-Preston-1995" TYPE="STUDY">Preston 1995</LINK>). The general lack of blinding raises the possibility of some detection bias with regard to all the main outcome measures. </P>
<P>The number of patients included for study ranged from 30 to 103, but a power calculation was provided in only two studies (<LINK REF="STD-Preston-1995" TYPE="STUDY">Preston 1995</LINK>, n = 103; <LINK REF="STD-Irvine-1998" TYPE="STUDY">Irvine 1998</LINK>, n = 44). The number of patients who withdrew or were lost to follow up before the end of the study period was disappointingly high in some trials. Three trials did not report any withdrawals or losses to follow up (<LINK REF="STD-Buyru-1995" TYPE="STUDY">Buyru 1995</LINK>; <LINK REF="STD-Cameron-1987" TYPE="STUDY">Cameron 1987</LINK>; <LINK REF="STD-Cameron-1990" TYPE="STUDY">Cameron 1990</LINK>) and it is unclear whether this was because there were no withdrawals or whether the information was missing in the publication. One trial reported a 20% post-randomisation exclusion rate and a further 27% of patients did not complete the three cycles of treatment (<LINK REF="STD-Bonduelle-1991" TYPE="STUDY">Bonduelle 1991</LINK>); intention-to-treat analysis was not performed in this study. Fifty-five per cent of patients were excluded after randomisation in the largest trial (<LINK REF="STD-Preston-1995" TYPE="STUDY">Preston 1995</LINK>), although an intention-to-treat analysis was performed. Intention-to-treat analysis was also carried out in the other two trials, which both lost 18% of patients to follow up (<LINK REF="STD-Higham-1993" TYPE="STUDY">Higham 1993</LINK>; <LINK REF="STD-Irvine-1998" TYPE="STUDY">Irvine 1998</LINK>). Trials of medical therapy for menorrhagia require a high degree of patient compliance, especially when objective measurements of menstrual blood loss are made, and recruiting patients to these trials can be difficult. The number of women lost to follow up must be borne in mind when interpreting the results of these trials. </P>
<P>
<B>Results</B>
<BR/>Based on the available evidence, this review was not able to meet all of its objectives in determining the effectiveness of oral progestogens in the treatment of menorrhagia. No RCTs comparing oral progestogens with placebo were identified and cost effectiveness was not assessed by any of the trials under consideration. </P>
<P>This review does not support the hypothesis that treatment with oral progestogen is more effective than other medical therapies in reducing menstrual blood loss. Oral progestogens administered during the luteal phase of the cycle were less effective at reducing menstrual blood loss when compared with tranexamic acid, danazol and the progesterone-releasing IUS. A comparison between luteal phase progestogen and mefenamic acid, a non steroidal anti inflammatory drug (NSAID), did not reach statistical significance for its findings. Administration of oral progestogens from days 5 to 26 of the cycle produced a significant reduction in MBL from baseline, but oral therapy was less effective than the levonorgestrel intrauterine system it was compared with. </P>
<P>Oral progestogens in the luteal phase were associated with a lower incidence of adverse events than danazol, but no difference was observed when oral progestogens were compared with mefenamic acid or tranexamic acid. Patients treated with the longer course of norethisterone, from day 5 to day 26, had a lower incidence of intermenstrual bleeding and breast tenderness than those treated with a levonorgestrel intrauterine system. Without placebo studies it is difficult to put these findings into context, since both danazol and the levonorgestrel intrauterine system are associated with a significant number of adverse effects. A high incidence of adverse effects can result in poor patient compliance, but no difference in patient compliance was noted when luteal phase progestogen was compared with mefenamic acid or danazol; the levonorgestrel intrauterine system was associated with a higher degree of patient acceptability than the longer regimen of norethisterone. Quality of life was assessed in only two of the seven trials (<LINK REF="STD-Irvine-1998" TYPE="STUDY">Irvine 1998</LINK>; <LINK REF="STD-Preston-1995" TYPE="STUDY">Preston 1995</LINK>). No significant difference was demonstrated in improved general health, symptoms of dysmenorrhoea or an ability to enjoy life between progestogen- and tranexamic acid-treated patients; although a greater proportion of these patients had improvement in their sex life and flooding and leakage problems with tranexamic acid (<LINK REF="STD-Preston-1995" TYPE="STUDY">Preston 1995</LINK>). There was no difference in the proportion of women who reported that their periods interfered with their daily life between norethisterone and LNG IUS groups (<LINK REF="STD-Irvine-1998" TYPE="STUDY">Irvine 1998</LINK>). Comparisons of progestogens with the LNG IUS, however, are based on a follow up of only three months, which may not be sufficient to adequately assess all of the effects arising from the wearing of a long-term medicated device. </P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>Progestogens administered from day 15 or 19 to day 26 of the cycle offer no advantage over other medical therapies such as danazol, tranexamic acid, NSAIDs and the progesterone-releasing intrauterine system in the treatment of menorrhagia in women with ovulatory cycles. </P>
<P>Progestogen therapy for 21 days of the cycle results in a significant reduction in menstrual blood loss, although women find the treatment less acceptable than using intrauterine levonorgestrel. This regimen of progestogen may have a role in the short-term treatment of menorrhagia. </P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Quality of life issues merit further attention since the majority of women complaining of menorrhagia will be offered treatment based on their symptoms alone with no objective measurement of menstrual blood loss. Longer duration of progestogen use, which results in a significant reduction in MBL, has at present only been compared with the levonorgestrel intrauterine system and merits further assessment against other forms of medical therapy.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>The authors acknowledge the helpful comments of those who refereed previous versions of this review and we are grateful to Ms Jenny Higham who provided additional material for the review. Special thanks are due to Ms Ruth Jepson and Ms Sarah Hetrick, Review Group Coordinators, for their professionalism and help with the inevitable problems that arise; to Mrs Sue Furness, Trials Search Coordinator, for her assistance with identifying trials and to Mrs Sue Hall, Secretary of the Review Group, for her secretarial help.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>There was no conflict of interest.<BR/> </P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Anne Lethaby registered the title, prepared the protocol, conducted searches for relevant studies, assessed the included trials for quality, performed data extraction, entered data, wrote all sections of the review except for the discussion and conclusions and incorporated suggested changes from the peer review process.<BR/>Gill Irvine read and commented on the draft of the protocol, assessed the included trials for quality, performed data extraction and wrote the discussion and conclusions sections of the review.<BR/>Iain Cameron read and commented on both the draft of the protocol and the final review.<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES>
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Bonduelle-1991" NAME="Bonduelle 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bonduelle M, Walker JJ, Calder AA</AU>
<TI>A comparative study of danazol and norethisterone in dysfunctional uterine bleeding presenting as menorrhagia</TI>
<SO>Postgraduate Medical Journal</SO>
<YR>1991</YR>
<VL>67</VL>
<PG>833-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Buyru-1995" NAME="Buyru 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Buyru F, Yalcin O, Kovanci E, Turfanda A</AU>
<TI>Danazol therapy in dysfunctional uterine bleeding [Turkish]</TI>
<SO>Istanbul Tip Fakultesi Mecmuasi</SO>
<YR>1995</YR>
<VL>58</VL>
<NO>3</NO>
<PG>37-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cameron-1987" NAME="Cameron 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cameron IT, Leask R, Kelly RW, Baird DT</AU>
<TI>The effects of danazol, mefenamic acid, norethisterone and a progesterone-impregnated coil on endometrial prostaglandin concentrations in women with menorrhagia</TI>
<SO>Prostaglandins</SO>
<YR>1987</YR>
<VL>34</VL>
<PG>99-110</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cameron-1990" NAME="Cameron 1990" YEAR="1990">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Cameron IT, Haining R, Lumsden MA, Thomas VR, Smith SK</AU>
<TI>The effects of mefenamic acid and norethisterone on measured menstrual blood loss</TI>
<SO>Obstetrics and Gynecology</SO>
<YR>1990</YR>
<VL>76</VL>
<PG>85-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Smith S, Haining R, Reed-Thomas V, Cameron I</AU>
<TI>The diagnosis and treatment of menorrhagia (abstract)</TI>
<SO>Silver Jubilee British Congress of Obstetrics and Gynaecology</SO>
<YR>1989</YR>
<PG>62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Higham-1993" NAME="Higham 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Higham JM, Shaw RW</AU>
<TI>A comparative study of danazol, a regimen of decreasing doses of danazol, and norethindrone in the treatment of objectively proven unexplained menorrhagia</TI>
<SO>American Journal of Obstetrics and Gynecolgy</SO>
<YR>1993</YR>
<VL>169</VL>
<PG>1134-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Irvine-1998" NAME="Irvine 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Irvine GA, Campbell-Brown MB, Lumsden MA, Heikkila A, Walker JJ, Cameron IT</AU>
<TI>Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia</TI>
<SO>British Journal of Obstetrics and Gynaecology</SO>
<YR>1988</YR>
<VL>105</VL>
<NO>6</NO>
<PG>592-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Preston-1995" NAME="Preston 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Preston JT, Cameron IT, Adams EJ, Smith SK</AU>
<TI>Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia</TI>
<SO>British Journal of Obstetrics &amp; Gynaecology</SO>
<YR>1995</YR>
<VL>102</VL>
<PG>401-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES/>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES>
<ADDITIONAL_REFERENCES>
<REFERENCE ID="REF-Bishop-1960" NAME="Bishop 1960" TYPE="JOURNAL_ARTICLE">
<AU>Bishop PMF, de Almeida JCC</AU>
<TI>Treatment of functional menstrual disorders with norethisterone</TI>
<SO>British Medical Journal</SO>
<YR>1960</YR>
<VL>1</VL>
<PG>1103-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bradlow-1992" NAME="Bradlow 1992" TYPE="BOOK">
<AU>Bradlow J, Coulter A, Brooks P</AU>
<SO>Patterns of referral</SO>
<YR>1992</YR>
<PB>Oxford Health Services Research Unit</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clarke-1995" NAME="Clarke 1995" TYPE="JOURNAL_ARTICLE">
<AU>Clarke A, Black N, Rowe P, Mott S, Howie K</AU>
<TI>Indications for and outcomes of total abdominal hysterectomy for benign disease: a prospective cohort study</TI>
<SO>British Journal of Obstetrics and Gynaecology</SO>
<YR>1995</YR>
<VL>102</VL>
<PG>611-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cole-1971" NAME="Cole 1971" TYPE="JOURNAL_ARTICLE">
<AU>Cole S, Billewicz W, Thomson A</AU>
<TI>Sources of variation in menstrual blood loss</TI>
<SO>Journal of Obstetrics and Gynaecology of the British Commonwealth</SO>
<YR>1971</YR>
<VL>78</VL>
<PG>939</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Conyngham-1965" NAME="Conyngham 1965" TYPE="JOURNAL_ARTICLE">
<AU>Conyngham RB</AU>
<TI>Norethisterone in menorrhagia</TI>
<SO>New Zealand Medical Journal</SO>
<YR>1965</YR>
<VL>64</VL>
<PG>697-701</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Coulter-1995" NAME="Coulter 1995" TYPE="JOURNAL_ARTICLE">
<AU>Coulter A, Kelland J, Peto V, Rees MCP</AU>
<TI>Treating menorrhagia in primary care</TI>
<SO>International Journal of Technology Assessment in Health Care</SO>
<YR>1995</YR>
<VL>11</VL>
<NO>3</NO>
<PG>456-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Farquhar-1996" NAME="Farquhar 1996" TYPE="JOURNAL_ARTICLE">
<AU>Farquhar CM, Kimble RM</AU>
<TI>How do New Zealand gynaecologists treat menorrhagia?</TI>
<SO>The Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology</SO>
<YR>1996</YR>
<VL>36</VL>
<NO>4</NO>
<PG>444-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gath-1982" NAME="Gath 1982" TYPE="JOURNAL_ARTICLE">
<AU>Gath D, Cooper P, Day A</AU>
<TI>Hysterectomy and psychiatric disorder. Levels of psychiatric morbidity before and after hysterectomy</TI>
<SO>International Journal of Psychiatry</SO>
<YR>1982</YR>
<VL>140</VL>
<PG>335-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hallberg-1964" NAME="Hallberg 1964" TYPE="JOURNAL_ARTICLE">
<AU>Hallberg L, Nilsson L</AU>
<TI>Determination of menstrual blood loss</TI>
<SO>Scandinavian Journal of Clinical and Laboratory Investigation</SO>
<YR>1964</YR>
<VL>16</VL>
<PG>244-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hallberg-1966" NAME="Hallberg 1966" TYPE="JOURNAL_ARTICLE">
<AU>Hallberg L, Hogdahl AM, Nilsson L, Rybo G</AU>
<TI>Menstrual blood loss - a population study</TI>
<SO>Acta Obstetricia et Gynecologica Scandinavica</SO>
<YR>1966</YR>
<VL>45</VL>
<PG>320-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higham-1990" NAME="Higham 1990" TYPE="JOURNAL_ARTICLE">
<AU>Higham JM, O'Brien PM, Shaw RW</AU>
<TI>Assessment of menstrual blood loss in patients complaining of menorrhagia</TI>
<SO>British Journal of Obstetrics and Gynaecology</SO>
<YR>1990</YR>
<VL>97</VL>
<PG>734-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Newton-1977" NAME="Newton 1977" TYPE="JOURNAL_ARTICLE">
<AU>Newton J, Barnard G, Collins W</AU>
<TI>A rapid method for measuring menstrual blood loss using automatic extraction</TI>
<SO>Contraception</SO>
<YR>1977</YR>
<VL>16</VL>
<PG>269-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vessey-1992" NAME="Vessey 1992" TYPE="JOURNAL_ARTICLE">
<AU>Vessey M, Villard-Mackintosh L, McPherson K, Coulter A, Yeates D</AU>
<TI>The epidemiology of hysterectomy: findings in a large cohort study</TI>
<SO>British Journal of Obstetrics and Gynaecology</SO>
<YR>1992</YR>
<VL>99</VL>
<PG>402-7</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Bonduelle-1991">
<CHAR_METHODS>
<P>Randomisation technique not stated.<BR/>Single centre, parallel group design with no blinding.<BR/>Number of patients randomised: n=30 (15 in each treatment group).<BR/>Withdrawals post randomization: n=6 (2, selection criteria not met; 4, did not return), 5 from danazol group and 1 from NET group.<BR/>Loss to follow up: n=8 (during treatment), 4 from each group, all because of adverse events.<BR/>No power calculations made and not intention to treat.<BR/>Source of funding not stated.</P>
<P/>
<P/>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Patients (with mean ages 39 and 32) recruited from the Menstrual Disorders Clinic at the Royal Infirmary, Glasgow, UK.<BR/>Inclusion criteria: complaint of MBL requiring more than 5 pads/tampons per day for longer than 6 days cycle; presence of flooding or clots on any day of the cycle; presence of secondary anaemia; excessive menstrual loss proving socially and domestically disruptive.<BR/>Exclusion criteria: underlying pathology (from history, examination and D &amp; C within the last year).<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Rx 1: Norethisterone 5mg tds from day 19 to day 26.<BR/>Rx 2: Danazol 200mg, daily.<BR/>Duration: 3 cycles (1 pre-Rx).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Duration of menstruation (days).<BR/>Prevalence of side effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Considered by authors to be a "pilot study". Poor quality study because of high proportion of participants excluded or lost to follow up.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Buyru-1995">
<CHAR_METHODS>
<P>Method of randomisation not stated.<BR/>Single centre, parallel group and no blinding.<BR/>Number of patients randomised: n=40<BR/>No withdrawals/exclusions reported.<BR/>No power calculation reported.<BR/>No source of funding given.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Patients aged 25 to 50 years with a complaint of menorrhagia recruited from Istanbul University Obstetrics and Gynaecology out-patient's department.<BR/>Inclusion criteria: women using &gt;3 pads per day during menstruation.<BR/>Exclusion criteria: organic pathology confirmed by ultrasound.<BR/>Women &gt;35 years also had endometrial biopsies.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Rx 1: Norethisterone 5mg bd on days 16-25 of the menstrual cycle.<BR/>Rx 2: Danazol 200mg daily continuously.<BR/>Duration: 3 months<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Duration of menstruation (days)<BR/>Side effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Paper written in Turkish and translated by Metin Gulmezoglu of the Pregnancy and Childbirth and Infectious Diseases Group.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Cameron-1987">
<CHAR_METHODS>
<P>Randomisation computer generated and assignment in sealed envelopes.<BR/>Single centre, parallel group design with no blinding.<BR/>Number of patients randomised: n=30.<BR/>No withdrawals/exclusions reported.<BR/>No power calculation. Intention-to-treat analysis.<BR/>Source of funding, Birthright Research Grant, RCOG.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Patients, aged between 29 and 50, recruited from Royal Infirmary, Edinburgh, UK.<BR/>Inclusion criteria: MBL&gt;50 ml/cycle.<BR/>No exclusion criteria stated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Rx 1: Norethisterone, 5mg bds, days 15-25 of cycle.<BR/>Rx 2: Danazol, 200mg, daily.<BR/>Rx 3: Mefenamic acid, 500mg tds, for first 5 days of menstruation.<BR/>Rx 4: Progesterone releasing IUS, 65ug progesterone daily.<BR/>Duration: 2 cycles.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Menstrual blood loss (alkaline haematin method).<BR/>Duration of menstruation (days).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Groups not comparable at baseline. Baseline MBL in danazol group significantly greater than in mefenamic acid and progesterone IUS groups.<BR/>Original data not available from principal author; MBL data reported as median and range. Median substituted for mean in meta-analysis and standard deviation estimated from the range.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Cameron-1990">
<CHAR_METHODS>
<P>Randomization technique centralized and controlled by pharmacy.<BR/>Single centre with parallel group design and no blinding.<BR/>Menstrual blood loss over 2 cycles assessed in 102 women with a subjective complaint of menorrhagia. 20 women refused to collect sanitary pads, 10 women had anovulatory cycles and 40 women had MBL&lt;80 ml/cycle. The remaining women (n=32) were randomised to treatment arms. <BR/>No withdrawals/exclusions reported.<BR/>No power calculation or intention-to-treat analysis.<BR/>No source of funding stated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Patients aged 21 to 51 years recruited from the Outpatient Department, Royal Infirmary, Edinburgh, UK.<BR/>Inclusion criteria: MBL&gt;80 ml/cycle over 2 cycles measured by the alkaline haematin method.<BR/>Exclusions were organic disease, anovulatory cycles and non compliance with collecting pads.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Rx 1: Norethisterone 5mg 2 times daily on days 19 to 26 of the menstrual cycle<BR/>Rx 2: Mefenamic acid 500mg 3 times daily on days 1 to 5 of the menstrual cycle<BR/>Duration over 2 cycles</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>MBL<BR/>Number of days bleeding<BR/>Cycle length<BR/>Side effects<BR/>Patient compliance</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Original data provided by the lead author.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Higham-1993">
<CHAR_METHODS>
<P>Randomisation method in sequential order and controlled by pharmacy.<BR/>Parallel group design with single blinding.<BR/>Number of patients randomised: n=57.<BR/>Exclusions post randomisation: n=3 (2 from reducing danazol group because of pharmacy error, 1 from NET group because of menopausal symptoms)<BR/>Loss to follow up during Rx: n=10 (5 from danazol reducing group (3, side effects; 2, study too demanding); 3 from danazol group (side effects) and 2 from NET group (side effects)).<BR/>No power calculation made. Intention-to-treat analysis.<BR/>Source of funding: Sanofi Winthrop Ltd.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Patients aged 26 to 48 years recruited from Royal Free Hospital and Edgware General Hospital, London.<BR/>Inclusion criteria: MBL&gt;80 ml/cycle, regular cycle between 21 and 35 days, aged 20 to 50 years, weight 45 to 110 kg, endometrial sampling within previous 3 years, no sensitivity to danazol or NET or ingestion 10 weeks previously, informed consent.<BR/>Exclusion criteria: Underlying pathological conditions (from clinical assessment, pelvic US or endometrial biopsy), concomitant treatment with hormonal, anti-prostaglandin or anti-coagulant medication, pregnancy or lactation or desire to become pregnant, perimenopausal, IUD wearers.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Rx 1: Norethindrone 5mg, tds daily on days 19 to 26 of the cycle<BR/>Rx 2: Danazol 200mg/day <BR/>Rx 3: Danazol 200mg/day for 1 cycle, 100mg/day during next cycle and 50mg/day during last cycle.<BR/>Duration: 3 cycles</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Menstrual blood loss (alkaline haematin method)<BR/>Improvement in MBL (patient assessment)<BR/>Duration of menstruation<BR/>Side effects<BR/>Treatment acceptability</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Comparison between NET group and danazol 200mg/day group. Comparisons between NET and reducing danazol group used in sensitivity analysis.<BR/>A similar proportion of anovulatory patients were found in each treatment group but there was no difference in response of these patients to medication compared to ovulatory women.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Irvine-1998">
<CHAR_METHODS>
<P>Randomisation technique by computer generated numbers with results sealed in opaque consecutively numbered envelopes.<BR/>Single centre, parallel group design with no blinding.<BR/>Number of patients randomised: n=44.<BR/>Number of withdrawals: n=10 (2 from the LNG IUS group and 8 from the NET group)<BR/>Power calculation for sample size and intention-to-treat analysis.<BR/>Source of funding not stated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Patients aged 30 to 45 years with a complaint of heavy regular periods recruited from gynaecology outpatient clinics in the UK.<BR/>Inclusion criteria: parous, aged 18 to 45 years, in good health, regular menstrual cycle, normal pelvic exam and uterine measurement &lt;10 cm, negative cervical cytology and MBL&gt;80 ml.<BR/>Exclusion criteria: treatment with steroid hormones or anticoagulants in the previous 3 months, treatment with injectable hormones for contraception in the previous 12 months.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Rx 1: Norethisterone (NET) 5mg daily from day 5 to 26 of the cycle.<BR/>Rx 2: Levonorgestrel intrauterine system (Mirena) fitted into the uterus within 7 days of the onset of a menstrual period.<BR/>Duration: 3 menstrual cycles.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>MBL (alkaline haematin method)<BR/>Proportion with no improvement in quality of life<BR/>Proportion who found the treatment unacceptable<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Preston-1995">
<CHAR_METHODS>
<P>Randomization by computer generated numbers with adequate concealment.<BR/>Single centre, parallel group design with double blinding.<BR/>Number of patients randomised: n=103.<BR/>Exclusions post randomisation: n=57 (33, MBL&lt;80 ml/cycle; 8, anovulation; 10 protocol violations; 10, other reasons).<BR/>Loss to follow up during treatment: n=4<BR/>Power calculation and intention to treat analysis.<BR/>Source of funding: Pharmacia.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Patients with mean age 40 years recruited from GPs and gynaecology centres, Cambridge, UK.<BR/>Inclusion criteria: 18+ years, cycle length 28 +/- 7 days, no hormone therapy in previous 3 months, no contraindication to either Rx drug, normal renal function, normal pelvic examination, negative cervical cytology.<BR/>After randomisation, participants proceeded to 2 placebo cycles and were only included in the treatment phase if they had MBL&gt;80 ml/cycle, were ovulatory and complied with the protocol.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Rx 1: Norethisterone 5mg 2 times daily on days 19 to 26<BR/>Rx 2: Tranexamic acid 1g 4 times daily on days 1 to 4 of menses<BR/>Duration 2 cycles</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>MBL (alkalin haematin method)<BR/>Improvement in MBL (patient perception)<BR/>Quality of life (social activities, sex life, general health)<BR/>Adverse events (abdominal pain, dysmenorrhoea, headache, gastrointestinal symptoms, weight gain)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Large number of exclusions post randomisation.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Bonduelle-1991">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Buyru-1995">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Cameron-1987">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Cameron-1990">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Higham-1993">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Irvine-1998">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Preston-1995">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Progestagen therapy versus placebo</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.01" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Menstrual blood loss (alkaline haematin method)</NAME>
<GROUP_LABEL_1>Progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Proportion of patients with no improvement in MBL (subjective)</NAME>
<GROUP_LABEL_1>Progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.03" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Duration of menstruation (days)</NAME>
<GROUP_LABEL_1>Progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Proportion with no improvement in quality of life - dysmenorrhoea</NAME>
<GROUP_LABEL_1>Progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Proportion of patient non-compliance with treatment</NAME>
<GROUP_LABEL_1>Progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Proportion of who find treatment unacceptable</NAME>
<GROUP_LABEL_1>Progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events (total)</NAME>
<GROUP_LABEL_1>Progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events - headache</NAME>
<GROUP_LABEL_1>Progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events - gastrointestinal symptoms</NAME>
<GROUP_LABEL_1>Progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events - weight gain</NAME>
<GROUP_LABEL_1>Progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.11" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="11" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events - skin changes</NAME>
<GROUP_LABEL_1>Progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.12" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="12" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events - neurological symptoms</NAME>
<GROUP_LABEL_1>Progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.13" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="13" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events - bloating</NAME>
<GROUP_LABEL_1>Progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.14" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="14" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events - voice changes</NAME>
<GROUP_LABEL_1>Progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.15" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="15" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events - dysmenorrhoea</NAME>
<GROUP_LABEL_1>Progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>Progestagen therapy (luteal phase only) versus NSAIDs</NAME>
<CONT_OUTCOME CHI2="3.418449298264086" CI_END="46.57333156095926" CI_START="-0.6242763073810629" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="22.9745276267891" ESTIMABLE="YES" I2="70.74696996360872" I2_Q="0.0" ID="CMP-002.01" NO="1" P_CHI2="0.06447164558966834" P_Q="1.0" P_Z="0.05637627259137662" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="23" TOTAL_2="25" UNITS="" WEIGHT="100.0" Z="1.9081156331455638">
<NAME>Menstrual blood loss (alkaline haematin method)</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>NSAIDs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NSAIDs</GRAPH_LABEL_2>
<CONT_DATA CI_END="96.34548554810895" CI_START="13.654514451891046" EFFECT_SIZE="55.0" ESTIMABLE="YES" MEAN_1="106.0" MEAN_2="51.0" ORDER="96235" SD_1="46.0" SD_2="38.0" SE="21.095023109728988" STUDY_ID="STD-Cameron-1987" TOTAL_1="8" TOTAL_2="8" WEIGHT="32.57795289850337"/>
<CONT_DATA CI_END="36.240149619522185" CI_START="-21.24014961952218" EFFECT_SIZE="7.5" ESTIMABLE="YES" MEAN_1="94.8" MEAN_2="87.3" ORDER="96236" SD_1="41.3" SD_2="41.5" SE="14.663611089908189" STUDY_ID="STD-Cameron-1990" TOTAL_1="15" TOTAL_2="17" WEIGHT="67.42204710149663"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Proportion of patients with no improvement in MBL (subjective)</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>NSAIDs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NSAIDs</GRAPH_LABEL_2>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="1.5431917701379083" CI_END="0.9544716715167183" CI_START="-0.13327319383618774" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.4105992388402653" ESTIMABLE="YES" I2="35.19923969587822" I2_Q="0.0" ID="CMP-002.03" NO="3" P_CHI2="0.21414380628544905" P_Q="1.0" P_Z="0.13895740921488373" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="23" TOTAL_2="25" UNITS="" WEIGHT="99.99999999999999" Z="1.479684705191203">
<NAME>Duration of menstruation (days)</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>NSAIDs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NSAIDs</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.8458556054991189" CI_START="-0.8458556054991189" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="5.0" MEAN_2="5.0" ORDER="96237" SD_1="1.0" SD_2="0.7" SE="0.4315669125408017" STUDY_ID="STD-Cameron-1987" TOTAL_1="8" TOTAL_2="8" WEIGHT="41.34296587996204"/>
<CONT_DATA CI_END="1.4101285874471552" CI_START="-0.010128587447156723" EFFECT_SIZE="0.6999999999999993" ESTIMABLE="YES" MEAN_1="6.1" MEAN_2="5.4" ORDER="96238" SD_1="1.12" SD_2="0.9" SE="0.36231716146243487" STUDY_ID="STD-Cameron-1990" TOTAL_1="15" TOTAL_2="17" WEIGHT="58.65703412003795"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Proportion with no improvement in quality of life - dysmenorrhoea</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>NSAIDs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NSAIDs</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="19.15987614582866" CI_START="0.06764567197787238" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.1384562779911171" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="1.2823926973648103" LOG_CI_START="-1.169759984672516" LOG_EFFECT_SIZE="0.05631635634614716" METHOD="PETO" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.9282670193877539" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="17" WEIGHT="100.0" Z="0.09002541398626664">
<NAME>Proportion of patient non-compliance with treatment</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>NSAIDs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NSAIDs</GRAPH_LABEL_2>
<DICH_DATA CI_END="19.159876145828655" CI_START="0.06764567197787241" EFFECT_SIZE="1.1384562779911171" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.28239269736481" LOG_CI_START="-1.169759984672516" LOG_EFFECT_SIZE="0.05631635634614716" ORDER="96239" O_E="0.0625" SE="1.4404066237802662" STUDY_ID="STD-Cameron-1990" TOTAL_1="15" TOTAL_2="17" VAR="0.4819808467741935" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Proportion of patients who find treatment unacceptable</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>NSAIDs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NSAIDs</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.860993309552934" CI_START="0.44232827251673906" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.8647089828925565" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-002.07" LOG_CI_END="0.8954774266502881" LOG_CI_START="-0.35425530072627615" LOG_EFFECT_SIZE="0.27061106296200593" METHOD="PETO" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.3959913805402192" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="17" WEIGHT="100.0" Z="0.848802188828041">
<NAME>Adverse events (total)</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>NSAIDs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NSAIDs</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.8609933095529305" CI_START="0.4423282725167391" EFFECT_SIZE="1.8647089828925565" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.8954774266502878" LOG_CI_START="-0.3542553007262761" LOG_EFFECT_SIZE="0.27061106296200593" ORDER="96240" O_E="1.15625" SE="0.7340991903377652" STUDY_ID="STD-Cameron-1990" TOTAL_1="15" TOTAL_2="17" VAR="1.855626260080645" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.313783189352581" CI_START="0.3499028314265073" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.5997229280078658" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-002.08" LOG_CI_END="0.8641420819162423" LOG_CI_START="-0.4560525431760454" LOG_EFFECT_SIZE="0.20404476937009847" METHOD="PETO" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.5446139222706823" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="17" WEIGHT="100.0" Z="0.6058506701937502">
<NAME>Adverse events - headache</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>NSAIDs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NSAIDs</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.313783189352581" CI_START="0.3499028314265073" EFFECT_SIZE="1.5997229280078658" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.8641420819162423" LOG_CI_START="-0.4560525431760454" LOG_EFFECT_SIZE="0.20404476937009847" ORDER="96241" O_E="0.78125" SE="0.7754888578480003" STUDY_ID="STD-Cameron-1990" TOTAL_1="15" TOTAL_2="17" VAR="1.6628339213709673" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.831071260303625" CI_START="0.053622417205715554" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.5591745128993798" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-002.09" LOG_CI_END="0.7657483488756043" LOG_CI_START="-1.2706536126686478" LOG_EFFECT_SIZE="-0.25245263189652184" METHOD="PETO" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.6270003207028164" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="17" WEIGHT="100.0" Z="0.48595324072887197">
<NAME>Adverse events - gastrointestinal symptoms</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>NSAIDs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NSAIDs</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.831071260303625" CI_START="0.053622417205715554" EFFECT_SIZE="0.5591745128993798" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7657483488756043" LOG_CI_START="-1.2706536126686478" LOG_EFFECT_SIZE="-0.25245263189652184" ORDER="96242" O_E="-0.40625" SE="1.1961925925633772" STUDY_ID="STD-Cameron-1990" TOTAL_1="15" TOTAL_2="17" VAR="0.6988722278225805" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events - weight gain</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>NSAIDs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NSAIDs</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.11" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="11" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events - skin changes</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>NSAIDs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NSAIDs</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.12" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="12" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events - neurological changes</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>NSAIDs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NSAIDs</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.13" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="13" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events - bloating</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>NSAIDs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NSAIDs</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.14" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="14" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events - voice changes</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>NSAIDs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NSAIDs</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="6.6889920362168285" CI_START="0.20165089014420096" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.1613962279388526" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-002.15" LOG_CI_END="0.82536067889042" LOG_CI_START="-0.6953998565531574" LOG_EFFECT_SIZE="0.06498041116863135" METHOD="PETO" NO="15" P_CHI2="1.0" P_Q="1.0" P_Z="0.866981230568773" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="17" WEIGHT="100.0" Z="0.16749417495105295">
<NAME>Adverse events - dysmenorrhoea</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>NSAIDs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NSAIDs</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.6889920362168285" CI_START="0.20165089014420107" EFFECT_SIZE="1.1613962279388526" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.82536067889042" LOG_CI_START="-0.6953998565531572" LOG_EFFECT_SIZE="0.06498041116863135" ORDER="96243" O_E="0.1875" SE="0.8933022664056158" STUDY_ID="STD-Cameron-1990" TOTAL_1="15" TOTAL_2="17" VAR="1.253150201612903" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>Progestagen therapy (luteal phase only) versus danazol</NAME>
<CONT_OUTCOME CHI2="0.017235095511119496" CI_END="96.53951701980314" CI_START="14.729460104535647" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="55.634488562169395" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.01" NO="1" P_CHI2="0.8955518378955201" P_Q="1.0" P_Z="0.007682229932674614" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="26" TOTAL_2="25" UNITS="" WEIGHT="100.0" Z="2.6657259019656814">
<NAME>Menstrual blood loss (alkaline haematin method)</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Danazol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours danazol</GRAPH_LABEL_2>
<CONT_DATA CI_END="119.95169977619646" CI_START="-15.951699776196463" EFFECT_SIZE="52.0" ESTIMABLE="YES" MEAN_1="106.0" MEAN_2="54.0" ORDER="96244" SD_1="46.0" SD_2="75.0" SE="34.66987164671943" STUDY_ID="STD-Cameron-1987" TOTAL_1="8" TOTAL_2="6" WEIGHT="36.23704276895811"/>
<CONT_DATA CI_END="108.9262392758367" CI_START="6.47376072416332" EFFECT_SIZE="57.70000000000002" ESTIMABLE="YES" MEAN_1="140.3" MEAN_2="82.6" ORDER="96245" SD_1="67.1" SD_2="90.7" SE="26.13631662617412" STUDY_ID="STD-Higham-1993" TOTAL_1="18" TOTAL_2="19" WEIGHT="63.76295723104188"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.029432057382441923" CI_END="11.96804812143844" CI_START="1.456239213915798" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="4.174726456723837" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="1.0780233267464188" LOG_CI_START="0.16323272164618124" LOG_EFFECT_SIZE="0.6206280241963001" METHOD="PETO" NO="2" P_CHI2="0.8637852679903768" P_Q="1.0" P_Z="0.007827411816094863" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="28" TOTAL_2="26" WEIGHT="100.0" Z="2.6594251590236095">
<NAME>Proportion of patients with no improvement in MBL (subjective)</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Danazol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours danazol</GRAPH_LABEL_2>
<DICH_DATA CI_END="31.262340236865928" CI_START="0.731794563288621" EFFECT_SIZE="4.783054528334126" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.49502148532473" LOG_CI_START="-0.1356108213355036" LOG_EFFECT_SIZE="0.6797053319946131" ORDER="96246" O_E="1.7058823529411766" SE="0.9578414886923188" STUDY_ID="STD-Bonduelle-1991" TOTAL_1="10" TOTAL_2="7" VAR="1.0899653979238755" WEIGHT="31.47250466356638"/>
<DICH_DATA CI_END="13.996840895922912" CI_START="1.0989080525429669" EFFECT_SIZE="3.9218925496107615" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="6" LOG_CI_END="1.1460300259435425" LOG_CI_START="0.04096135580495766" LOG_EFFECT_SIZE="0.5934956908742501" ORDER="96247" O_E="3.243243243243244" SE="0.6491228070175439" STUDY_ID="STD-Higham-1993" TOTAL_1="18" TOTAL_2="19" VAR="2.373265157048941" WEIGHT="68.52749533643362"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="19.385144220113723" CI_END="2.1062139326062908" CI_START="1.0983893941266327" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.6023016633664617" ESTIMABLE="YES" I2="84.52423172128249" I2_Q="0.0" ID="CMP-003.03" NO="3" P_CHI2="2.275776044550204E-4" P_Q="1.0" P_Z="4.6009583214788104E-10" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="56" TOTAL_2="51" UNITS="" WEIGHT="100.0" Z="6.2321434588294125">
<NAME>Duration of menstruation (days)</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Danazol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours danazol</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.087430335479704" CI_START="-1.8874303354797046" EFFECT_SIZE="0.5999999999999996" ESTIMABLE="YES" MEAN_1="5.8" MEAN_2="5.2" ORDER="96248" SD_1="2.2" SD_2="2.6" SE="1.2691204303243515" STUDY_ID="STD-Bonduelle-1991" TOTAL_1="10" TOTAL_2="6" WEIGHT="4.104006239788345"/>
<CONT_DATA CI_END="2.927632372307292" CI_START="1.6723676276927084" EFFECT_SIZE="2.3000000000000003" ESTIMABLE="YES" MEAN_1="4.65" MEAN_2="2.35" ORDER="96249" SD_1="1.22" SD_2="0.75" SE="0.32022648235272483" STUDY_ID="STD-Buyru-1995" TOTAL_1="20" TOTAL_2="20" WEIGHT="64.4613199104695"/>
<CONT_DATA CI_END="2.05850153016853" CI_START="-0.0585015301685301" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="5.0" MEAN_2="4.0" ORDER="96250" SD_1="1.0" SD_2="1.0" SE="0.5400617248673216" STUDY_ID="STD-Cameron-1987" TOTAL_1="8" TOTAL_2="6" WEIGHT="22.663495029322615"/>
<CONT_DATA CI_END="0.20147647995191043" CI_START="-3.2014764799519106" EFFECT_SIZE="-1.5" ESTIMABLE="YES" MEAN_1="5.7" MEAN_2="7.2" ORDER="96251" SD_1="1.4" SD_2="3.5" SE="0.8681161967122558" STUDY_ID="STD-Higham-1993" TOTAL_1="18" TOTAL_2="19" WEIGHT="8.771178820419532"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Proportion with no improvement in quality of life - dysmenorrhoea</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Danazol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours danazol</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.006517382343473974" CI_END="2.231391136980963" CI_START="0.1835755301678026" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.6400225081846858" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="0.3485757037413143" LOG_CI_START="-0.7361852088719185" LOG_EFFECT_SIZE="-0.19380475256530208" METHOD="PETO" NO="5" P_CHI2="0.9356564347572472" P_Q="1.0" P_Z="0.48371545519739867" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="32" TOTAL_2="29" WEIGHT="100.0" Z="0.7003392741090091">
<NAME>Proportion of patient non-compliance with treatment</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Danazol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours danazol</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.2948271649274963" CI_START="0.11326013814820199" EFFECT_SIZE="0.6108785311943258" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5178326379628178" LOG_CI_START="-0.9459229129817375" LOG_EFFECT_SIZE="-0.2140451375094599" ORDER="96252" O_E="-0.666666666666667" SE="0.8598172563316662" STUDY_ID="STD-Bonduelle-1991" TOTAL_1="14" TOTAL_2="10" VAR="1.352657004830918" WEIGHT="54.92005272508454"/>
<DICH_DATA CI_END="4.351805812935951" CI_START="0.10544790317580732" EFFECT_SIZE="0.677413314013229" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6386695079557629" LOG_CI_START="-0.9769620517540855" LOG_EFFECT_SIZE="-0.1691462718991613" ORDER="96253" O_E="-0.43243243243243246" SE="0.9490299756787676" STUDY_ID="STD-Higham-1993" TOTAL_1="18" TOTAL_2="19" VAR="1.110299488677867" WEIGHT="45.07994727491546"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Proportion who find treatment unacceptable</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Danazol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours danazol</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.523850671838056" CI_END="0.8768506953156184" CI_START="0.13204675345207975" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.3402723726349616" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="28" I2="0.0" I2_Q="0.0" ID="CMP-003.07" LOG_CI_END="-0.05707434930294384" LOG_CI_START="-0.8792722720426664" LOG_EFFECT_SIZE="-0.4681733106728052" METHOD="PETO" NO="7" P_CHI2="0.4692037716231412" P_Q="1.0" P_Z="0.02561014896730896" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="38" TOTAL_2="39" WEIGHT="100.0" Z="2.2320728429572037">
<NAME>Adverse events (total)</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Danazol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours danazol</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5562585878427442" CI_START="0.1329154356361398" EFFECT_SIZE="0.45480851813219386" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" LOG_CI_END="0.19208176099719285" LOG_CI_START="-0.8764245809659534" LOG_EFFECT_SIZE="-0.3421714099843803" ORDER="96254" O_E="-2.0" SE="0.6276459144608478" STUDY_ID="STD-Buyru-1995" TOTAL_1="20" TOTAL_2="20" VAR="2.5384615384615383" WEIGHT="59.21047458026973"/>
<DICH_DATA CI_END="0.9831145349801693" CI_START="0.0507268711235717" EFFECT_SIZE="0.22331664585437688" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="17" LOG_CI_END="-0.007395882969248308" LOG_CI_START="-1.2947619245084214" LOG_EFFECT_SIZE="-0.6510789037388348" ORDER="96255" O_E="-2.621621621621621" SE="0.7562051853647912" STUDY_ID="STD-Higham-1993" TOTAL_1="18" TOTAL_2="19" VAR="1.7487216946676405" WEIGHT="40.789525419730275"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.7367987836987451" CI_END="0.9505953121342533" CI_START="0.0910393713495001" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.2941795363795454" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-003.08" LOG_CI_END="-0.022004331761485148" LOG_CI_START="-1.0407707498548233" LOG_EFFECT_SIZE="-0.5313875408081541" METHOD="PETO" NO="8" P_CHI2="0.3906883042988931" P_Q="1.0" P_Z="0.04089130090140917" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="34" TOTAL_2="30" WEIGHT="100.0" Z="2.044630492957355">
<NAME>Adverse events - headache</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Danazol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours danazol</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.048075673935109" CI_START="0.020956599801349098" EFFECT_SIZE="0.1482029097561425" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.020392641031247775" LOG_CI_START="-1.6786791800519043" LOG_EFFECT_SIZE="-0.8291432695103284" ORDER="96256" O_E="-1.9166666666666665" SE="0.9980431982454013" STUDY_ID="STD-Bonduelle-1991" TOTAL_1="14" TOTAL_2="10" VAR="1.0039251207729472" WEIGHT="35.95222450490315"/>
<DICH_DATA CI_END="1.871735609714447" CI_START="0.09983010490551911" EFFECT_SIZE="0.4322679288047969" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.27224450286825724" LOG_CI_START="-1.0007384725124215" LOG_EFFECT_SIZE="-0.36424698482208223" ORDER="96257" O_E="-1.5" SE="0.747756501105966" STUDY_ID="STD-Buyru-1995" TOTAL_1="20" TOTAL_2="20" VAR="1.7884615384615383" WEIGHT="64.04777549509686"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.20118080996052912" CI_END="0.8953713789272704" CI_START="0.056350466112787836" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.22462100201584284" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-003.09" LOG_CI_END="-0.04799679220923692" LOG_CI_START="-1.2491024872598537" LOG_EFFECT_SIZE="-0.6485496397345453" METHOD="PETO" NO="9" P_CHI2="0.6537694241582845" P_Q="1.0" P_Z="0.03429327563373313" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="34" TOTAL_2="30" WEIGHT="100.0" Z="2.1166062925254354">
<NAME>Adverse events - gastrointestinal symptoms</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Danazol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours danazol</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3159335233254112" CI_START="0.05485193877622163" EFFECT_SIZE="0.26866615911763636" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.11923395068967109" LOG_CI_START="-1.2608080174067902" LOG_EFFECT_SIZE="-0.5707870333585595" ORDER="96258" O_E="-2.0" SE="0.8106434833777776" STUDY_ID="STD-Bonduelle-1991" TOTAL_1="14" TOTAL_2="10" VAR="1.5217391304347827" WEIGHT="75.74916759156493"/>
<DICH_DATA CI_END="2.1284848474346996" CI_START="0.007745265347095721" EFFECT_SIZE="0.12839657289294878" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.3280705628058871" LOG_CI_START="-2.1109636990402896" LOG_EFFECT_SIZE="-0.8914465681172012" ORDER="96259" O_E="-1.0" SE="1.4327007988227578" STUDY_ID="STD-Buyru-1995" TOTAL_1="20" TOTAL_2="20" VAR="0.48717948717948717" WEIGHT="24.25083240843507"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.088945897286245" CI_END="0.6488481905897729" CI_START="0.09152646436991646" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.24369403110765683" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-003.10" LOG_CI_END="-0.1878569021230508" LOG_CI_START="-1.038453313933057" LOG_EFFECT_SIZE="-0.6131551080280538" METHOD="PETO" NO="10" P_CHI2="0.5801475885250621" P_Q="1.0" P_Z="0.004717853808515586" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="52" TOTAL_2="49" WEIGHT="100.0" Z="2.8256924482305106">
<NAME>Adverse events - weight gain</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Danazol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours danazol</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5132686795001975" CI_START="0.05683486432563091" EFFECT_SIZE="0.29326851192656256" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.17991604346599804" LOG_CI_START="-1.2453851724019755" LOG_EFFECT_SIZE="-0.5327345644679887" ORDER="96260" O_E="-1.75" SE="0.8372289895556536" STUDY_ID="STD-Bonduelle-1991" TOTAL_1="14" TOTAL_2="10" VAR="1.426630434782609" WEIGHT="35.61506829150934"/>
<DICH_DATA CI_END="0.6851882034750091" CI_START="0.016923008584556903" EFFECT_SIZE="0.10768215195400163" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="-0.16419012266188376" LOG_CI_START="-1.771522425249753" LOG_EFFECT_SIZE="-0.9678562739558184" ORDER="96261" O_E="-2.5" SE="0.9441549509633318" STUDY_ID="STD-Buyru-1995" TOTAL_1="20" TOTAL_2="20" VAR="1.1217948717948718" WEIGHT="28.005010964263747"/>
<DICH_DATA CI_END="1.933218903629891" CI_START="0.07516959177538644" EFFECT_SIZE="0.3812076544330124" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.28628103315730985" LOG_CI_START="-1.1239578082769652" LOG_EFFECT_SIZE="-0.4188383875598278" ORDER="96262" O_E="-1.4054054054054053" SE="0.8283812762533432" STUDY_ID="STD-Higham-1993" TOTAL_1="18" TOTAL_2="19" VAR="1.4572680788897006" WEIGHT="36.379920744226915"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.08210736547561837" CI_END="0.7547147361031579" CI_START="0.04438067665077375" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.1830157115292791" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-003.11" LOG_CI_END="-0.1222171701546117" LOG_CI_START="-1.3528060805750113" LOG_EFFECT_SIZE="-0.7375116253648114" METHOD="PETO" NO="11" P_CHI2="0.7744616406228955" P_Q="1.0" P_Z="0.01880998051894405" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="34" TOTAL_2="30" WEIGHT="100.0" Z="2.349275556856449">
<NAME>Adverse events - skin changes</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Danazol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours danazol</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0658747347240067" CI_START="0.04003178467697138" EFFECT_SIZE="0.2065644400014084" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.02770616790371559" LOG_CI_START="-1.3975950479642583" LOG_EFFECT_SIZE="-0.6849444400302712" ORDER="96263" O_E="-2.25" SE="0.8372289895556536" STUDY_ID="STD-Bonduelle-1991" TOTAL_1="14" TOTAL_2="10" VAR="1.426630434782609" WEIGHT="74.5439982524484"/>
<DICH_DATA CI_END="2.1284848474346996" CI_START="0.007745265347095721" EFFECT_SIZE="0.12839657289294878" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.3280705628058871" LOG_CI_START="-2.1109636990402896" LOG_EFFECT_SIZE="-0.8914465681172012" ORDER="96264" O_E="-1.0" SE="1.4327007988227578" STUDY_ID="STD-Buyru-1995" TOTAL_1="20" TOTAL_2="20" VAR="0.48717948717948717" WEIGHT="25.456001747551603"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.898024848560199" CI_START="0.2041639295263999" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-003.12" LOG_CI_END="0.6900209840482306" LOG_CI_START="-0.6900209840482305" LOG_EFFECT_SIZE="0.0" METHOD="PETO" NO="12" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="14" TOTAL_2="10" WEIGHT="100.0" Z="0.0">
<NAME>Adverse events - neurological changes</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Danazol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours danazol</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.8980248485602" CI_START="0.20416392952639983" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.6900209840482306" LOG_CI_START="-0.6900209840482308" LOG_EFFECT_SIZE="0.0" ORDER="96265" O_E="0.0" SE="0.8106434833777776" STUDY_ID="STD-Bonduelle-1991" TOTAL_1="14" TOTAL_2="10" VAR="1.5217391304347827" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0658747347240065" CI_START="0.0400317846769714" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.2065644400014084" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-003.13" LOG_CI_END="0.0277061679037155" LOG_CI_START="-1.397595047964258" LOG_EFFECT_SIZE="-0.6849444400302712" METHOD="PETO" NO="13" P_CHI2="1.0" P_Q="1.0" P_Z="0.05959673913600269" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="14" TOTAL_2="10" WEIGHT="100.0" Z="1.883765226500221">
<NAME>Adverse events - bloating</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Danazol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours danazol</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0658747347240067" CI_START="0.04003178467697138" EFFECT_SIZE="0.2065644400014084" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.02770616790371559" LOG_CI_START="-1.3975950479642583" LOG_EFFECT_SIZE="-0.6849444400302712" ORDER="96266" O_E="-2.25" SE="0.8372289895556536" STUDY_ID="STD-Bonduelle-1991" TOTAL_1="14" TOTAL_2="10" VAR="1.426630434782609" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="106.326344405764" CI_START="0.3388839702124241" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="6.002690540949023" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.14" LOG_CI_END="2.0266408827033757" LOG_CI_START="-0.46994897354366805" LOG_EFFECT_SIZE="0.7783459545798537" METHOD="PETO" NO="14" P_CHI2="1.0" P_Q="1.0" P_Z="0.2216732265076683" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="14" TOTAL_2="10" WEIGHT="100.0" Z="1.2220910332321782">
<NAME>Adverse events - voice changes</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Danazol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours danazol</GRAPH_LABEL_2>
<DICH_DATA CI_END="106.326344405764" CI_START="0.3388839702124241" EFFECT_SIZE="6.002690540949023" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0266408827033757" LOG_CI_START="-0.46994897354366805" LOG_EFFECT_SIZE="0.7783459545798537" ORDER="96267" O_E="0.8333333333333333" SE="1.4665092398786141" STUDY_ID="STD-Bonduelle-1991" TOTAL_1="14" TOTAL_2="10" VAR="0.4649758454106281" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.15" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="15" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events - dysmenorrhoea</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Danazol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours danazol</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.016919414702043" CI_START="0.27999049674521215" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.4016671332893371" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-003.16" LOG_CI_END="0.8461464889342325" LOG_CI_START="-0.5528567089476208" LOG_EFFECT_SIZE="0.14664488999330577" METHOD="PETO" NO="16" P_CHI2="1.0" P_Q="1.0" P_Z="0.6811526817927827" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.00000000000001" Z="0.4108907018066591">
<NAME>Adverse events - muscle cramps</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Danazol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours danazol</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.016919414702047" CI_START="0.27999049674521215" EFFECT_SIZE="1.4016671332893371" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.8461464889342327" LOG_CI_START="-0.5528567089476208" LOG_EFFECT_SIZE="0.14664488999330577" ORDER="96268" O_E="0.5" SE="0.8217814036133182" STUDY_ID="STD-Buyru-1995" TOTAL_1="20" TOTAL_2="20" VAR="1.4807692307692308" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.6709074173963643" CI_START="0.04126863309261544" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.26259486883840705" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-003.17" LOG_CI_END="0.2229523869204435" LOG_CI_START="-1.3843799156674255" LOG_EFFECT_SIZE="-0.580713764373491" METHOD="PETO" NO="17" P_CHI2="1.0" P_Q="1.0" P_Z="0.156707464864142" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="1.416232426444998">
<NAME>Adverse events - intermenstrual bleeding</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Danazol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours danazol</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6709074173963647" CI_START="0.04126863309261544" EFFECT_SIZE="0.26259486883840705" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.22295238692044358" LOG_CI_START="-1.3843799156674255" LOG_EFFECT_SIZE="-0.580713764373491" ORDER="96269" O_E="-1.5" SE="0.9441549509633318" STUDY_ID="STD-Buyru-1995" TOTAL_1="20" TOTAL_2="20" VAR="1.1217948717948718" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="67.1320691203735" CI_START="1.1350440642063548" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="8.729138363720136" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.18" LOG_CI_END="1.8269300330587799" LOG_CI_START="0.05501272185531185" LOG_EFFECT_SIZE="0.9409713774570458" METHOD="PETO" NO="18" P_CHI2="1.0" P_Q="1.0" P_Z="0.03737298834172431" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="2.0816659994661326">
<NAME>Adverse events - breast changes</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Danazol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours danazol</GRAPH_LABEL_2>
<DICH_DATA CI_END="67.1320691203735" CI_START="1.1350440642063548" EFFECT_SIZE="8.729138363720136" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.8269300330587799" LOG_CI_START="0.05501272185531185" LOG_EFFECT_SIZE="0.9409713774570458" ORDER="96270" O_E="2.0" SE="1.0408329997330665" STUDY_ID="STD-Buyru-1995" TOTAL_1="20" TOTAL_2="20" VAR="0.923076923076923" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" NO="4">
<NAME>Progestagen therapy (luteal phase only) versus tranexamic acid</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="178.46084263689346" CI_START="43.539157363106554" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="111.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.01" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.0012600668987897419" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="21" TOTAL_2="25" UNITS="" WEIGHT="100.0" Z="3.224922692634253">
<NAME>Menstrual blood loss (alkaline haematin method)</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Tranexamic acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours TXA</GRAPH_LABEL_2>
<CONT_DATA CI_END="178.46084263689346" CI_START="43.539157363106554" EFFECT_SIZE="111.0" ESTIMABLE="YES" MEAN_1="208.0" MEAN_2="97.0" ORDER="96271" SD_1="135.0" SD_2="89.0" SE="34.41942972881949" STUDY_ID="STD-Preston-1995" TOTAL_1="21" TOTAL_2="25" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="9.923811072843" CI_START="0.9405166593216325" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="3.055079317786909" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="0.9966784876837279" LOG_CI_START="-0.026633507410380796" LOG_EFFECT_SIZE="0.48502249013667353" METHOD="PETO" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.06317740526959152" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="24" WEIGHT="100.0" Z="1.8579409152189008">
<NAME>Proportion of patients with no improvement in MBL (subjective)</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Tranexamic acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours TXA</GRAPH_LABEL_2>
<DICH_DATA CI_END="9.923811072843" CI_START="0.9405166593216325" EFFECT_SIZE="3.055079317786909" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="10" LOG_CI_END="0.9966784876837279" LOG_CI_START="-0.026633507410380796" LOG_EFFECT_SIZE="0.48502249013667353" ORDER="96272" O_E="3.0909090909090917" SE="0.6010985313943501" STUDY_ID="STD-Preston-1995" TOTAL_1="20" TOTAL_2="24" VAR="2.7676340572746487" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-004.03" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Duration of menstruation (days)</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Tranexamic acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours TXA</GRAPH_LABEL_2>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="1.5723800379914856" CI_END="5.224424592222791" CI_START="1.7384358809412808" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="3.0136899589028925" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="52" I2="0.0" I2_Q="0.0" ID="CMP-004.04" LOG_CI_END="0.7180384650828946" LOG_CI_START="0.24015867714932315" LOG_EFFECT_SIZE="0.4790985711161089" METHOD="PETO" NO="4" P_CHI2="0.8137475195762088" P_Q="0.8137475195762088" P_Z="8.497224096733308E-5" Q="1.5723800379914856" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="100" TOTAL_2="120" WEIGHT="500.0" Z="3.929925341653935">
<NAME>Proportion with no improvement in quality of life/dysmenorrhoea</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Tranexamic acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours TXA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.401532923217533" CI_START="0.6807275587510896" DF="0.0" EFFECT_SIZE="2.2446441673097515" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="12" I2="0.0" ID="CMP-004.04.01" LOG_CI_END="0.869321675291713" LOG_CI_START="-0.16702666694901866" LOG_EFFECT_SIZE="0.3511475041713472" NO="1" P_CHI2="1.0" P_Z="0.18411362041896448" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="24" WEIGHT="100.0" Z="1.328195228158332">
<NAME>No improvement in general health</NAME>
<DICH_DATA CI_END="7.401532923217533" CI_START="0.6807275587510896" EFFECT_SIZE="2.2446441673097515" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="12" LOG_CI_END="0.869321675291713" LOG_CI_START="-0.16702666694901866" LOG_EFFECT_SIZE="0.3511475041713472" ORDER="96273" O_E="2.1818181818181817" SE="0.6087561462392356" STUDY_ID="STD-Preston-1995" TOTAL_1="20" TOTAL_2="24" VAR="2.698443205842783" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.226443980308105" CI_START="0.6286518566856394" DF="0.0" EFFECT_SIZE="2.274108458746216" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="15" I2="0.0" ID="CMP-004.04.02" LOG_CI_END="0.9152121446327479" LOG_CI_START="-0.20158979744581673" LOG_EFFECT_SIZE="0.3568111735934656" NO="2" P_CHI2="1.0" P_Z="0.21042699264740095" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="24" WEIGHT="99.99999999999999" Z="1.2523922517954664">
<NAME>No improvement in dysmenorrhoea symptoms</NAME>
<DICH_DATA CI_END="8.226443980308105" CI_START="0.6286518566856394" EFFECT_SIZE="2.274108458746216" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="15" LOG_CI_END="0.9152121446327479" LOG_CI_START="-0.20158979744581673" LOG_EFFECT_SIZE="0.3568111735934656" ORDER="96274" O_E="1.9090909090909083" SE="0.6560149890357208" STUDY_ID="STD-Preston-1995" TOTAL_1="20" TOTAL_2="24" VAR="2.3236594272535074" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.747215405038077" CI_START="0.7252068253214304" DF="0.0" EFFECT_SIZE="2.370302404540177" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" I2="0.0" ID="CMP-004.04.03" LOG_CI_END="0.8891456313402709" LOG_CI_START="-0.13953811717238448" LOG_EFFECT_SIZE="0.37480375708394326" NO="3" P_CHI2="1.0" P_Z="0.153223783064119" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="24" WEIGHT="100.0" Z="1.4282365522289389">
<NAME>No improvement in ability to enjoy social activities</NAME>
<DICH_DATA CI_END="7.747215405038077" CI_START="0.7252068253214304" EFFECT_SIZE="2.370302404540177" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" LOG_CI_END="0.8891456313402709" LOG_CI_START="-0.13953811717238448" LOG_EFFECT_SIZE="0.37480375708394326" ORDER="96275" O_E="2.3636363636363633" SE="0.6042539259430127" STUDY_ID="STD-Preston-1995" TOTAL_1="20" TOTAL_2="24" VAR="2.7388045358447046" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="18.26249717592969" CI_START="1.5368114216350586" DF="0.0" EFFECT_SIZE="5.297736709911765" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="4" I2="0.0" ID="CMP-004.04.04" LOG_CI_END="1.2615601617840644" LOG_CI_START="0.18662057955707778" LOG_EFFECT_SIZE="0.724090370670571" NO="4" P_CHI2="1.0" P_Z="0.008278285417465342" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="24" WEIGHT="100.0" Z="2.640503841390591">
<NAME>No improvement in flooding or leakage</NAME>
<DICH_DATA CI_END="18.26249717592969" CI_START="1.5368114216350586" EFFECT_SIZE="5.297736709911765" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="4" LOG_CI_END="1.2615601617840644" LOG_CI_START="0.18662057955707778" LOG_EFFECT_SIZE="0.724090370670571" ORDER="96276" O_E="4.181818181818182" SE="0.6314248316368805" STUDY_ID="STD-Preston-1995" TOTAL_1="20" TOTAL_2="24" VAR="2.508168364405151" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="14.132028922345757" CI_START="1.1382508384619918" DF="0.0" EFFECT_SIZE="4.0107098835529325" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="13" I2="0.0" ID="CMP-004.04.05" LOG_CI_END="1.1502045175826714" LOG_CI_START="0.05623797889174267" LOG_EFFECT_SIZE="0.6032212482372071" NO="5" P_CHI2="1.0" P_Z="0.030658488450526725" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="24" WEIGHT="100.0" Z="2.161477301982171">
<NAME>No improvement in sex life</NAME>
<DICH_DATA CI_END="14.132028922345757" CI_START="1.1382508384619918" EFFECT_SIZE="4.0107098835529325" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="13" LOG_CI_END="1.1502045175826714" LOG_CI_START="0.05623797889174267" LOG_EFFECT_SIZE="0.6032212482372071" ORDER="96277" O_E="3.3636363636363633" SE="0.6426013600487537" STUDY_ID="STD-Preston-1995" TOTAL_1="20" TOTAL_2="24" VAR="2.421679800115318" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-004.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Proportion of patient non-compliance with treatment</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Tranexamic acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours TXA</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-004.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Proportion who find treatment unacceptable</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Tranexamic acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours TXA</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="18.69593511218893" CI_START="0.31834083654019096" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.4396064484902795" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="22" I2="0.0" I2_Q="0.0" ID="CMP-004.07" LOG_CI_END="1.2717471920848982" LOG_CI_START="-0.49710764681256836" LOG_EFFECT_SIZE="0.387319772636165" METHOD="PETO" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.39070889283434496" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="21" TOTAL_2="25" WEIGHT="100.0" Z="0.8583325077599878">
<NAME>Adverse events (total)</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Tranexamic acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours TXA</GRAPH_LABEL_2>
<DICH_DATA CI_END="18.69593511218893" CI_START="0.31834083654019096" EFFECT_SIZE="2.4396064484902795" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="22" LOG_CI_END="1.2717471920848982" LOG_CI_START="-0.49710764681256836" LOG_EFFECT_SIZE="0.387319772636165" ORDER="96278" O_E="0.8260869565217384" SE="1.039034088341039" STUDY_ID="STD-Preston-1995" TOTAL_1="21" TOTAL_2="25" VAR="0.9262759924385633" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="6.154926082516683" CI_START="0.5861031078349332" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.8993212749446362" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-004.08" LOG_CI_END="0.7892228416462329" LOG_CI_START="-0.2320259757485915" LOG_EFFECT_SIZE="0.2785984329488207" METHOD="PETO" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.2849061090078113" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="21" TOTAL_2="25" WEIGHT="100.0" Z="1.0693630884624672">
<NAME>Adverse events - headache</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Tranexamic acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours TXA</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.154926082516683" CI_START="0.5861031078349332" EFFECT_SIZE="1.8993212749446362" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.7892228416462329" LOG_CI_START="-0.2320259757485915" LOG_EFFECT_SIZE="0.2785984329488207" ORDER="96279" O_E="1.7826086956521738" SE="0.5998866106008962" STUDY_ID="STD-Preston-1995" TOTAL_1="21" TOTAL_2="25" VAR="2.77882797731569" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="13.706087898958287" CI_START="0.8483120113217097" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="3.4098444235650187" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-004.09" LOG_CI_END="1.1369135126783803" LOG_CI_START="-0.07144438374240235" LOG_EFFECT_SIZE="0.532734564467989" METHOD="PETO" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.08395281829267716" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="21" TOTAL_2="25" WEIGHT="100.0" Z="1.7281975195754296">
<NAME>Adverse events - gastrointestinal symptoms</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Tranexamic acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours TXA</GRAPH_LABEL_2>
<DICH_DATA CI_END="13.706087898958287" CI_START="0.8483120113217097" EFFECT_SIZE="3.4098444235650187" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="1.1369135126783803" LOG_CI_START="-0.07144438374240235" LOG_EFFECT_SIZE="0.532734564467989" ORDER="96280" O_E="2.4347826086956523" SE="0.7097954098256228" STUDY_ID="STD-Preston-1995" TOTAL_1="21" TOTAL_2="25" VAR="1.9848771266540641" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.5395036364305628" CI_START="0.009135338753184606" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.15231292126322493" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-004.10" LOG_CI_END="0.4047488390510494" LOG_CI_START="-2.0392753436687427" LOG_EFFECT_SIZE="-0.8172632523088467" METHOD="PETO" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.18992725319597376" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="21" TOTAL_2="25" WEIGHT="100.0" Z="1.3107943462579545">
<NAME>Adverse events - weight gain</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Tranexamic acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours TXA</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.539503636430564" CI_START="0.009135338753184606" EFFECT_SIZE="0.15231292126322493" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.4047488390510497" LOG_CI_START="-2.0392753436687427" LOG_EFFECT_SIZE="-0.8172632523088467" ORDER="96281" O_E="-0.9130434782608695" SE="1.4356319030444264" STUDY_ID="STD-Preston-1995" TOTAL_1="21" TOTAL_2="25" VAR="0.4851921865154379" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-004.11" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="11" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events - skin changes</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Tranexamic acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours TXA</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-004.12" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="12" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events - neurological changes</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Tranexamic acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours TXA</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-004.13" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="13" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events - bloating</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Tranexamic acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours TXA</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-004.14" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="14" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events - voice changes</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Tranexamic acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours TXA</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="6.705933152858604" CI_START="0.324718316473206" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.4756487806311176" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-004.15" LOG_CI_END="0.8264592199115701" LOG_CI_START="-0.48849321331768686" LOG_EFFECT_SIZE="0.1689830032969416" METHOD="PETO" NO="15" P_CHI2="1.0" P_Q="1.0" P_Z="0.6144403230103672" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="21" TOTAL_2="25" WEIGHT="100.0" Z="0.5037453706945995">
<NAME>Adverse events - dysmenorrhoea</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Tranexamic acid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours TXA</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.705933152858604" CI_START="0.324718316473206" EFFECT_SIZE="1.4756487806311176" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="20" LOG_CI_END="0.8264592199115701" LOG_CI_START="-0.48849321331768686" LOG_EFFECT_SIZE="0.1689830032969416" ORDER="96282" O_E="0.6521739130434767" SE="0.7724095683983877" STUDY_ID="STD-Preston-1995" TOTAL_1="21" TOTAL_2="25" VAR="1.6761184625078762" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" NO="5">
<NAME>Progestagen therapy (luteal phase only) versus progesterone releasing IUS</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="83.6203018583868" CI_START="18.379698141613204" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="51.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.01" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.0021818509446989444" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="8" TOTAL_2="8" UNITS="" WEIGHT="100.0" Z="3.064293017443159">
<NAME>Menstrual blood loss (alkaline haematin method)</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Progesterone IUS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours prog IUS</GRAPH_LABEL_2>
<CONT_DATA CI_END="83.6203018583868" CI_START="18.379698141613204" EFFECT_SIZE="51.0" ESTIMABLE="YES" MEAN_1="106.0" MEAN_2="55.0" ORDER="96283" SD_1="46.0" SD_2="10.0" SE="16.64331697709324" STUDY_ID="STD-Cameron-1987" TOTAL_1="8" TOTAL_2="8" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Proportion of patients with no improvement in MBL (subjective)</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Progesterone IUS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours prog IUS</GRAPH_LABEL_2>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-3.807800451410576" CI_START="-6.192199548589424" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-5.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.03" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="2.0358911935390394E-16" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="8" TOTAL_2="8" UNITS="" WEIGHT="100.0" Z="8.219949365267865">
<NAME>Duration of menstruation (days)</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Progesterone IUS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours prog IUS</GRAPH_LABEL_2>
<CONT_DATA CI_END="-3.807800451410576" CI_START="-6.192199548589424" EFFECT_SIZE="-5.0" ESTIMABLE="YES" MEAN_1="5.0" MEAN_2="10.0" ORDER="96284" SD_1="1.0" SD_2="1.4" SE="0.6082762530298219" STUDY_ID="STD-Cameron-1987" TOTAL_1="8" TOTAL_2="8" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-005.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Proportion with no improvement in quality of life - dysmenorrhoea</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Progesterone IUS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours prog IUS</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-005.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Proportion of patient non-compliance with treatment</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Progesterone IUS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours prog IUS</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-005.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Proportion who find treatment unacceptable</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Progesterone IUS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours prog IUS</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-005.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events (total)</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Progesterone IUS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours prog IUS</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-005.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events - headache</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Progesterone IUS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours prog IUS</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-005.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events - gastrointestinal symptoms</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Progesterone IUS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours prog IUS</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-005.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events - weight gain</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Progesterone IUS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours prog IUS</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-005.11" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="11" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events - skin changes</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Progesterone IUS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours prog IUS</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-005.12" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="12" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events - neurological changes</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Progesterone IUS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours prog IUS</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-005.13" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="13" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events - bloating</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Progesterone IUS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours prog IUS</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-005.14" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="14" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events - voice changes</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Progesterone IUS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours prog IUS</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-005.15" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="15" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events - dysmenorrhoea</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Progesterone IUS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours prog IUS</GRAPH_LABEL_2>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" NO="6">
<NAME>Progestagen therapy (3 to 4 weeks) versus progestagen releasing IUS</NAME>
<OTHER_OUTCOME COLS="1" ID="CMP-006.01" NO="1" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Menstrual blood loss (alkaline haematin method)</NAME>
<TR>
<TH>
<P>Menstrual Blood Loss</P>
</TH>
</TR>
<OTHER_DATA ORDER="96285" STUDY_ID="STD-Irvine-1998">
<TR>
<TD>
<P>Median menstrual blood loss (range) after 3 months of NET: 20 mls (4-137)<BR/>Median menstrual blood loss (range) after 3 months of LNG IUS: 6 mls (0-284)<BR/>p=0.033, t=315.5, Wilcoxon rank-sum test, n=44</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="14.23191245542948" CI_START="1.0325311355595665" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="3.8333918047584103" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-006.02" LOG_CI_END="1.1532632636143147" LOG_CI_START="0.013903156500674389" LOG_EFFECT_SIZE="0.5835832100574947" METHOD="PETO" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.044664835827542576" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="22" TOTAL_2="22" WEIGHT="100.0" Z="2.0077973005261263">
<NAME>Proportion of patients with MBL&gt;80mls after treatment</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Progestagen IUS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours prog IUS</GRAPH_LABEL_2>
<DICH_DATA CI_END="14.23191245542948" CI_START="1.0325311355595665" EFFECT_SIZE="3.8333918047584103" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" LOG_CI_END="1.1532632636143147" LOG_CI_START="0.013903156500674389" LOG_EFFECT_SIZE="0.5835832100574947" ORDER="96286" O_E="3.0" SE="0.6692657668420421" STUDY_ID="STD-Irvine-1998" TOTAL_1="22" TOTAL_2="22" VAR="2.2325581395348837" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-006.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Proportion of patients with no improvement in MBL (subjective)</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Progestagen IUS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours prog IUS</GRAPH_LABEL_2>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-006.04" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Duration of menstruation (days)</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Progestagen IUS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours prog IUS</GRAPH_LABEL_2>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.389441463428072" CI_START="0.092689812287615" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.47061330274163743" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-006.05" LOG_CI_END="0.37829639563456086" LOG_CI_START="-1.0329679973594283" LOG_EFFECT_SIZE="-0.3273358008624338" METHOD="PETO" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.36324039552756726" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="19" WEIGHT="100.00000000000001" Z="0.909207918411186">
<NAME>Proportion with no improvement in quality of life-dysmenorrhoea</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Progestagen IUS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours prog IUS</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.389441463428072" CI_START="0.092689812287615" EFFECT_SIZE="0.47061330274163743" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.37829639563456086" LOG_CI_START="-1.0329679973594283" LOG_EFFECT_SIZE="-0.3273358008624338" ORDER="96287" O_E="-1.096774193548387" SE="0.8289836903160813" STUDY_ID="STD-Irvine-1998" TOTAL_1="12" TOTAL_2="19" VAR="1.4551508844953174" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-006.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Proportion of patient non-compliance with treatment</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Progestagen IUS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours prog IUS</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="29.490098243517924" CI_START="2.5109134031077933" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="8.605061472099706" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-006.07" LOG_CI_END="1.4696762193658586" LOG_CI_START="0.39983173493476487" LOG_EFFECT_SIZE="0.9347539771503118" METHOD="PETO" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="6.14903283811658E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="18" TOTAL_2="22" WEIGHT="100.0" Z="3.4249541055388564">
<NAME>Proportion who find treatment unacceptable</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Progestagen IUS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours prog IUS</GRAPH_LABEL_2>
<DICH_DATA CI_END="29.490098243517938" CI_START="2.510913403107793" EFFECT_SIZE="8.605061472099706" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="5" LOG_CI_END="1.4696762193658588" LOG_CI_START="0.3998317349347648" LOG_EFFECT_SIZE="0.9347539771503118" ORDER="96288" O_E="5.449999999999999" SE="0.6284319459704324" STUDY_ID="STD-Irvine-1998" TOTAL_1="18" TOTAL_2="22" VAR="2.5321153846153845" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-006.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events (total)</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Progestagen IUS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours prog IUS</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-006.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events - headache</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Progestagen IUS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours prog IUS</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-006.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events - gastrointestinal symptoms</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Progestagen IUS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours prog IUS</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-006.11" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="11" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events - weight gain</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Progestagen IUS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours prog IUS</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-006.12" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="12" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events - skin changes</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Progestagen IUS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours prog IUS</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-006.13" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="13" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events - neurological changes</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Progestagen IUS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours prog IUS</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-006.14" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="14" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events - bloating</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Progestagen IUS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours prog IUS</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-006.15" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="15" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events - voice changes</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Progestagen IUS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours prog IUS</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-006.16" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="16" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events - dysmenorrhoea</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Progestagen IUS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours prog IUS</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.9926431012378167" CI_START="0.053579133244162976" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.23061863971743513" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-006.17" LOG_CI_END="-0.0032068713678377672" LOG_CI_START="-1.2710043163030602" LOG_EFFECT_SIZE="-0.6371055938354491" METHOD="PETO" NO="17" P_CHI2="1.0" P_Q="1.0" P_Z="0.04885219691789931" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="19" WEIGHT="100.0" Z="1.9698793734834923">
<NAME>Adverse events - intermenstrual bleeding</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Progestagen IUS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours prog IUS</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9926431012378167" CI_START="0.053579133244162976" EFFECT_SIZE="0.23061863971743513" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="10" LOG_CI_END="-0.0032068713678377672" LOG_CI_START="-1.2710043163030602" LOG_EFFECT_SIZE="-0.6371055938354491" ORDER="96289" O_E="-2.645161290322581" SE="0.7447104948535153" STUDY_ID="STD-Irvine-1998" TOTAL_1="12" TOTAL_2="19" VAR="1.8031217481789805" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.535357509329104" CI_START="0.19082527327484514" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.8213620169218944" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-006.18" LOG_CI_END="0.5484333379287096" LOG_CI_START="-0.7193641070065131" LOG_EFFECT_SIZE="-0.08546538453890165" METHOD="PETO" NO="18" P_CHI2="1.0" P_Q="1.0" P_Z="0.791585659096353" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="19" WEIGHT="100.0" Z="0.26425211107705354">
<NAME>Adverse events - mood swings</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Progestagen IUS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours prog IUS</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.535357509329104" CI_START="0.19082527327484522" EFFECT_SIZE="0.8213620169218944" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" LOG_CI_END="0.5484333379287096" LOG_CI_START="-0.7193641070065129" LOG_EFFECT_SIZE="-0.08546538453890165" ORDER="96290" O_E="-0.35483870967741904" SE="0.7447104948535153" STUDY_ID="STD-Irvine-1998" TOTAL_1="12" TOTAL_2="19" VAR="1.8031217481789803" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.45530756619582574" CI_START="0.026461153414081277" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.10976321496612476" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-006.19" LOG_CI_END="-0.3416951326265931" LOG_CI_START="-1.5773912292923815" LOG_EFFECT_SIZE="-0.9595431809594872" METHOD="PETO" NO="19" P_CHI2="1.0" P_Q="1.0" P_Z="0.0023352973555940213" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="19" WEIGHT="100.0" Z="3.043903887640505">
<NAME>Adverse events - breast tenderness</NAME>
<GROUP_LABEL_1>Oral progestagens</GROUP_LABEL_1>
<GROUP_LABEL_2>Progestagen IUS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestagens</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours prog IUS</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.45530756619582563" CI_START="0.02646115341408129" EFFECT_SIZE="0.10976321496612476" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="14" LOG_CI_END="-0.34169513262659323" LOG_CI_START="-1.577391229292381" LOG_EFFECT_SIZE="-0.9595431809594872" ORDER="96291" O_E="-4.193548387096774" SE="0.7258540039758128" STUDY_ID="STD-Irvine-1998" TOTAL_1="12" TOTAL_2="19" VAR="1.8980228928199792" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>